World epidemic prevention patent information table
Time interval
By application date
- World epidemic prevention patent information table: 1912.04-2019.08
By announcement date
- World epidemic prevention patent information table: 1913.06-2019.10
Field display
| World epidemic prevention patent information table |
|---|
| Classification |
| Classification number |
| Agent |
| PDF download address |
| Abstract |
| Application date |
| Country/Organization |
| Public/announcement date |
| Citing patents |
| Main classification number |
| Application number |
| Inventor |
| Master Claims |
| Public/Announcement Number |
| Applicant |
Sample data
| Category | Classification number | Agent | Abstract | Application date | Country/Organization | Public/announcement date | Citing patents | Main classification number | Application number | Inventor | Master Claims | Public/Announcement Number | Applicant |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | A61K31/53;A61K31/664;A61K31/675;A61K31/683;A61K31/685;A61P31/12 | Provided are methods for treating Arenaviridae and Coronaviridae virus infections by administering nucleosides and prodrugs thereof, of Formula (I): wherein the 1' position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Lassa virus and Junin virus infections. | 20160916 | WO(世界知识产权局) | 20170323 | WO2010002877A2;WO2014078778A2;WO2014116755A1;US2012071434A1;US8008264B2;US2012027752A1;WO2009132135A1;US2012009147A1;WO2012142085A1;WO2012075140A1;US2013143835A1 | A61K31/53 | WO2016US52092 | CLARKE MICHAEL O' NEIL HANRAHAN;FENG JOY YANG;JORDAN ROBERT;MACKMAN RICHARD L;RAY ADRIAN S;SIEGEL DUSTIN | WO2017049060A1 | GILEAD SCIENCES INC | ||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | A61K31/706;A61K45/06 | wherein the 1′ position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Lassa virus and Junin virus infections. | 20160916 | US(美国) | 20170316 | A61K31/706 | US201615267433 | CLARKE MICHAEL O' NEIL HANRAHAN;FENG JOY YANG;JORDAN ROBERT;MACKMAN RICHARD L;RAY ADRIAN S;SIEGEL DUSTIN | US2017071964A1 | GILEAD SCIENCES INC | |||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | A61K31/706;A61K31/7056 | wherein the 1′ position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Lassa virus and Junin virus infections. | 20190201 | US(美国) | 20190822 | A61K31/706 | US201916265016 | CLARKE MICHAEL O' NEIL HANRAHAN;FENG JOY YANG;JORDAN ROBERT;MACKMAN RICHARD L;RAY ADRIAN S;SIEGEL DUSTIN | US2019255085A1 | GILEAD SCIENCES INC | |||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | A61K31/706;A61P31/12 | Provided are methods of treating feline Coronavirus infections comprising administering a therapeutically effective amount of aza-sugar containing nucleoside analogs or pharmaceutically acceptable salts thereof. | 20180313 | WO(世界知识产权局) | 20180920 | A61K31/706 | WO2018US22166 | PERRON MICHEL JOSEPH | WO2018169946A1 | GILEAD SCIENCES INC | |||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | A61K31/724;A61K9/19;A61K47/40;A61K47/69;A61P31/12 | The present disclosure provides a composition comprising Compound 1, or a pharmaceutically acceptable salt thereof, cyclodextrin, and, optionally, pH adjusting agents. | 20180710 | US(美国) | 20190321 | A61K31/724 | US201816031620 | LARSON NATE | US2019083525A1 | GILEAD SCIENCES INC | |||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07D487/04;C07D519/00;C07F9/24;C07F9/6561 | Provided are methods of preparing compounds and pharmaceutical compositions for treating Filoviridae virus infections The compounds, compositions, and methods provided are particularly useful for the treatment of Marburg virus, Ebola virus and Cueva virus infections. | 20151029 | US(美国) | 20160505 | US8980865B2;US9243022B2;US9249174B2;US9605018B2;US9724360B2;US9388208B2;US9481703B2;US9487544B2;US9540411B2;US9701682B2;US2015133395A1 | C07D487/04 | US201514926063 | AXT STEVEN DONALD;BADALOV PAVEL ROBERTOVICH;BRAK KATRIEN;CAMPAGNA SILVIO;CHTCHEMELININE ANDREI;DOERFFLER EDWARD;FRICK MORIN MAE;GAO DETIAN;HEUMANN LARS V;HOANG BRITTANIE;LEW WILLARD;MILBURN ROBERT RONALD;NEVILLE SEAN TIMOTHY;ROSS BRUCE;RUEDEN ERIK;SCOTT ROBERT WILLIAM;SIEGEL DUSTIN;STEVENS ANDREW C;TADEUS CLARISSA;VIEIRA TIAGO;WALTMAN ANDREW W;WANG XIANGHONG;WHITCOMB MARK CHARLES;WOLFE LYDIA;YU CHIA-YUN | US2016122356A1 | GILEAD SCIENCES INC | ||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | A61K31/706;A61K31/00;A61K31/53;A61K31/6615;A61K31/665;A61K31/675;A61K31/683;A61K31/685;A61K31/7056;A61K45/06;C07D487/04;C07D519/00;C07F9/24;C07F9/6561;C07H1/00;C07H1/02;C07H11/00;C07H15/18 | Provided are compounds, methods, and pharmaceutical compositions for treating Filoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula IV: The compounds, compositions, and methods provided are particularly useful for the treatment of Marburg virus, Ebola virus and Cueva virus infections. | 20180222 | US(美国) | 20190409 | US8008264B2;US8318682B2;US8853171B2;US9724360B2;US9949994B2;US4816570A;US4968788A;US5663159A;US5792756A;US6312662B1;US6476030B1;US6656915B1;US6909011B2;US7105493B2;US7125855B2;US7176203B2;US7268119B2;US7285658B2;US7368437B1;US7429571B2;US7514410B2;US7560434B2;US7598230B2;US7608597B2;US7713941B2;US7807653B2;US7842672B2;US7973013B2;US7994139B2;US8012941B2;US8012942B2;US8071568B2;US8119607B2;US8242085B2;US8415308B2;US8455451B2;US8871737B2;US8980865B2;US9090642B2;US9243022B2;US9249174B2;US9278990B2;US9388208B2;US9481703B2;US9487544B2;US9540411B2;US9605018B2;US9701682B2;US2003050229A1;US2004006002A1;US2004023901A1;US2004063658A1;US2004067901A1;US2004138170A1;US2005187180A1;US2005215513A1;US2005250728A1;US2006058303A1;US2006241064A1;US2008107628A1;US2008161324A1;US2008280842A1;US2009004138A1;US2009221524A1;US2009233879A1;US2009317361A1;US2010015094A1;US2010016251A1;US2010021425A1;US2010035835A1;US2010035836A1;US2010203015A1;US2010234584A1;US2010291031A2;US2010298257A1;US2011070194A1;US2011230654A1;US2011257122A1;US2011293563A1;US2012009147A1;US2012020921A1;US2012027752A1;US2012071434A1;US2012107274A1;US2013034521A1;US2013143835A1;US2013281686A1;US2013315868A1;US2013344028A2;US2015111839A1;US2015133395A1;US2015152116A1;AU2010295392B2;CA2367921C;CN1291994A;CN1443189A;CN1498221A;CN1852915A;CN101043893A;CN101611046A;CN102906102A;EA201071170A1;EA201171417A1;EA201200525A1;EP2480559A1;EP2396340B1;JPH1017629A;JP2004520367A;JP2008502685A;JP2008518934A;TWI401084B;WO9119721A1;WO0056734A1;WO0132153A2;WO0160315A2;WO0190121A2;WO0208241A2;WO0218404A2;WO0232920A2;WO02057287A2;WO02057425A2;WO03093272A1;WO03093273A1;WO03100009A2;WO2004046331A2;WO2005009418A2;WO2005123087A2;WO2006031725A2;WO2006050161A2;WO2006065335A2;WO2006121820A1;WO2007027248A2;WO2007056170A2;WO2007064883A2;WO2007064931A2;WO2007065289A2;WO2007097991A2;WO2007135134A1;WO2008005542A2;WO2008055870A1;WO2008079206A1;WO2008082601A2;WO2008085508A2;WO2008089105A2;WO2008116064A2;WO2008121634A2;WO2008141079A1;WO2009009951A1;WO2009131926A1;WO2009132123A1;WO2009132135A1;WO2010002877A2;WO2010036407A2;WO2010093608A1;WO2010099458A1;WO2010135569A1;WO2011011303A1;WO2010111381A2;WO2011035231A1;WO2011035250A1;WO2011123645A2;WO2011123672A1;WO2011150288A1;WO2012012465A1;WO2012012776A1;WO2012039787A1;WO2012039791A1;WO2012051570A1;WO2013084165A1;WO2014042433A2;WO2014078778A2;WO2014116755A1;WO2015069939A1;WO2016069825A1;WO2016069826A1;WO2016069827A1;WO2017049060A1 | A61K31/706 | US201815902690 | CHUN BYOUNG KWON;CLARKE MICHAEL O'NEIL HANRAHAN;DOERFFLER EDWARD;HUI HON CHUNG;JORDAN ROBERT;MACKMAN RICHARD L;PARRISH JAY P;RAY ADRIAN S;SIEGEL DUSTIN | US10251898B2 | GILEAD SCIENCES INC | ||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07H15/18;A61K31/00;A61K31/53;A61K31/675;A61K31/685;A61K45/06;C07D487/04;C07D519/00;C07F9/24;C07F9/6561;C07H1/00;C07H1/02;C07H7/06;C07H11/00 | Provided are compounds, methods, and pharmaceutical compositions for treating Filoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula IV: The compounds, compositions, and methods provided are particularly useful for the treatment of Marburg virus, Ebola virus and Cueva virus infections. | 20160824 | US(美国) | 20180424 | US4816570A;US4968788A;US5663159A;US5792756A;US6312662B1;US6476030B1;US6656915B1;US6909011B2;US7105493B2;US7125855B2;US7176203B2;US7268119B2;US7285658B2;US7368437B1;US7429571B2;US7514410B2;US7560434B2;US7598230B2;US7608597B2;US7713941B2;US7807653B2;US7842672B2;US7973013B2;US7994139B2;US8008264B2;US8012941B2;US8012942B2;US8071568B2;US8119607B2;US8242085B2;US8318682B2;US8415308B2;US8455451B2;US9090642B2;US9724360B2;US2003050229A1;US2004006002A1;US2004023901A1;US2004063658A1;US2004067901A1;US2004138170A1;US2005187180A1;US2005215513A1;US2005250728A1;US2006058303A1;US2006241064A1;US2008107628A1;US2008161324A1;US2008280842A1;US2009004138A1;US2009221524A1;US2009233879A1;US2009317361A1;US2010015094A1;US2010016251A1;US2010021425A1;US2010035835A1;US2010035836A1;US2010203015A1;US2010234584A1;US2010291031A2;US2010298257A1;US2011070194A1;US2011230654A1;US2011257122A1;US2011293563A1;US2012009147A1;US2012020921A1;US2012027752A1;US2012107274A1;US2013034521A1;US2013143835A1;US2013281686A1;US2013344028A2;US2015111839A1;US2015152116A1;CA2367921C;CN1291994A;CN1443189A;CN1498221A;CN1852915A;CN101043893A;CN101611046A;CN102906102A;EA201071170A1;EA201171417A1;EA201200525A1;EP2396340B1;JPH1017629A;JP2004520367A;JP2008502685A;JP2008518934A;TWI401084B;WO9119721A1;WO0056734A1;WO0132153A2;WO0160315A2;WO0190121A2;WO0208241A2;WO0218404A2;WO0232920A2;WO02057287A2;WO02057425A2;WO03093272A1;WO03093273A1;WO03100009A2;WO2004046331A2;WO2005009418A2;WO2005123087A2;WO2006031725A2;WO2006050161A2;WO2006065335A2;WO2006121820A1;WO2007027248A2;WO2007056170A2;WO2007064883A2;WO2007064931A2;WO2007065289A2;WO2007097991A2;WO2007135134A1;WO2008005542A2;WO2008079206A1;WO2008082601A2;WO2008085508A2;WO2008089105A2;WO2008116064A2;WO2008121634A2;WO2008141079A1;WO2009009951A1;WO2009131926A1;WO2009132123A1;WO2009132135A1;WO2010002877A2;WO2010036407A2;WO2010093608A1;WO2010099458A1;WO2010135569A1;WO2010111381A2;WO2011035231A1;WO2011035250A1;WO2011123645A2;WO2011123672A1;WO2011150288A1;WO2012012465A1;WO2012012776A1;WO2012039787A1;WO2012039791A1;WO2012051570A1;WO2013084165A1;WO2014042433A2;WO2015069939A1 | C07H15/18 | US201615246240 | CHUN BYOUNG KWON;CLARKE MICHAEL O'NEIL HANRAHAN;DOERFFLER EDWARD;HUI HON CHUNG;JORDAN ROBERT;MACKMAN RICHARD L;PARRISH JAY P;RAY ADRIAN S;SIEGEL DUSTIN | US9949994B2 | GILEAD SCIENCES INC | ||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07D487/04;A61K9/00;A61K31/706;A61K45/06;C07F9/6561;C07H7/06;C07H19/04 | Provided are methods for treating Paramyxoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula I: wherein the 1′ position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Human parainfluenza and Human respiratory syncytial virus infections. | 20150204 | US(美国) | 20180904 | US9090642B2;US4816570A;US4968788A;US5663159A;US5792756A;US6312662B1;US6476030B1;US6656915B1;US6909011B2;US7105493B2;US7125855B2;US7176203B2;US7268119B2;US7285658B2;US7368437B1;US7429571B2;US7514410B2;US7560434B2;US7598230B2;US7608597B2;US7713941B2;US7807653B2;US7842672B2;US7973013B2;US7994139B2;US8008264B2;US8012941B2;US8012942B2;US8071568B2;US8119607B2;US8242085B2;US8318682B2;US8415308B2;US8455451B2;US2003050229A1;US2004006002A1;US2004023901A1;US2004063658A1;US2004067901A1;US2004138170A1;US2005187180A1;US2005215513A1;US2005250728A1;US2006058303A1;US2006241064A1;US2008107628A1;US2008161324A1;US2008280842A1;US2009004138A1;US2009221524A1;US2009233879A1;US2009317361A1;US2010015094A1;US2010016251A1;US2010021425A1;US2010035835A1;US2010035836A1;US2010203015A1;US2010234584A1;US2010291031A2;US2010298257A1;US2011070194A1;US2011230654A1;US2011257122A1;US2011293563A1;US2012009147A1;US2012020921A1;US2012027752A1;US2012107274A1;US2013034521A1;US2013281686A1;US2013344028A2;CA2367921C;CN1443189A;CN1498221A;CN1852915A;CN1291994C;CN101043893A;CN101611046A;CN102906102A;EA201071170A1;EA201171417A1;EA201200525A1;EP2396340B1;JPS4117629B1;JP2004520367A;JP2008502685A;JP2008518934A;TWI401084B;WO9119721A1;WO0056734A1;WO0132153A2;WO0160315A2;WO0190121A2;WO0208241A2;WO0218404A2;WO0232920A2;WO02057287A2;WO02057425A2;WO03093272A1;WO03093273A1;WO03100009A2;WO2004046331A2;WO2005009418A2;WO2005123087A2;WO2006031725A2;WO2006050161A2;WO2006065335A2;WO2006121820A1;WO2007027248A2;WO2007056170A2;WO2007064883A2;WO2007064931A2;WO2007065289A2;WO2007097991A2;WO2007135134A1;WO2008005542A2;WO2008079206A1;WO2008082601A2;WO2008085508A2;WO2008089105A2;WO2008116064A2;WO2008121634A2;WO2008141079A1;WO2009009951A1;WO2009131926A1;WO2009132123A1;WO2009132135A1;WO2010002877A2;WO2010036407A2;WO2010093608A1;WO2010099458A1;WO2010111381A2;WO2010135569A1;WO2011035231A1;WO2011035250A1;WO2011123672A1;WO2011123645A2;WO2011150288A1;WO2012012465A1;WO2012012776A1;WO2012039787A1;WO2012039791A1;WO2012051570A1 | C07D487/04 | US201514613719 | MACKMAN RICHARD L;PARRISH JAY P;RAY ADRIAN S;THEODORE DOROTHY AGNES | US10065958B2 | GILEAD SCIENCES INC | ||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07H19/23;A61K31/706;A61P31/16 | Provided are compounds of Formula I, as well as pharmaceutical compositions containing compounds of Formula I and methods for treating Orthomyxoviridae virus infections by administering these compounds. The compounds, compositions, and methods provided are particularly useful for the treatment of Human Influenza virus infections. | 20130311 | WO(世界知识产权局) | 20130919 | WO0232920A2;WO2009132123A1;WO2009132135A1;WO2012037038A1 | C07H19/23 | WO2013US30196 | CLARKE MICHAEL O' NEIL HANRAHAN | WO2013138236A1 | GILEAD SCIENCES INC | ||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07H19/23 | as well as pharmaceutical compositions containing compounds of Formula I and methods for treating Orthomyxoviridae virus infections by administering these compounds. The compounds, compositions, and methods provided are particularly useful for the treatment of Human Influenza virus infections. | 20160930 | US(美国) | 20170427 | C07H19/23 | US201615282492 | CLARKE MICHAEL O' NEIL HANRAHAN | US2017114086A1 | GILEAD SCIENCES INC | |||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07H19/23;A61K31/706;A61K45/06;C07H19/12 | as well as pharmaceutical compositions containing compounds of Formula I and methods for treating Orthomyxoviridae virus infections by administering these compounds. The compounds, compositions, and methods provided are particularly useful for the treatment of Human Influenza virus infections. | 20180622 | US(美国) | 20190117 | C07H19/23 | US201816016369 | CLARKE MICHAEL O' NEIL HANRAHAN | US2019016749A1 | GILEAD SCIENCES INC | |||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | A61K31/706;A61P31/16;C07H7/06;C07H21/04 | Provided are methods for treating Orthomyxoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula I wherein R2 is halogen. The compounds, compositions, and methods provided particularly useful for the treatment of Human Influenza virus infections. | 20110912 | WO(世界知识产权局) | 20120322 | WO2010002877A2;WO03062257A1;WO0232920A2;WO0056734A1;WO2008089105A2;WO2008141079A1;WO2009132123A1;WO2009132135A1;US4816570A;US4968788A;US5663159A;US5792756A;WO9119721A1;US6312662B1;US5458135A;US5740794A;US5775320A;US5785049A;US3906950A;US4013075A;US4069819A;US4995385A;US5522385A;US4668218A;US4667668A;US4805811A;US5388572A;US5261538A;US5544647A;US5622163A;US4955371A;US3565070A;US3361306A;US6116234A | A61K31/706 | WO2011US51249 | CLARKE MICHAEL O' NEIL HANRAHAN;KIM CHOUNG U;LEW WILLARD | WO2012037038A1 | GILEAD SCIENCES INC;CLARKE MICHAEL O' NEIL HANRAHAN;KIM CHOUNG U;LEW WILLARD | ||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07F9/6558;C07D487/04 | wherein R2 is halogen. The compounds, compositions, and methods provided are particularly useful for the treatment of Human Influenza virus infections. | 20170124 | US(美国) | 20170810 | C07F9/6558 | US201715414351 | CLARKE MICHAEL O' NEIL HANRAHAN;KIM CHOUNG U;LEW WILLARD | US2017226140A1 | GILEAD SCIENCES INC | |||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07H19/23;A61K31/706;A61P31/16 | Disclosed herein are compounds of Formula I, as well as pharmaceutical compositions containing compounds of Formula I and methods for treating Orthomyxoviridae virus infections by administering these compounds, wherein the variables are as defined in the specification. The compounds, compositions, and methods provided are particularly useful for the treatment of Human Influenza virus infections. | 20130311 | NZ(新西兰) | 20161028 | C07H19/23 | NZ20130629996 | CLARKE MICHAEL O’ NEIL HANRAHAN | NZ629996A | GILEAD SCIENCES INC | |||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07H19/23;A61K31/706;A61P31/16 | Provided are compounds of Formula I, as well as pharmaceutical compositions containing compounds of Formula I and methods for treating Orthomyxoviridae virus infections by administering these compounds. The compounds, compositions, and methods provided are particularly useful for the treatment of Human Influenza virus infections. | 20171219 | AU(澳大利亚) | 20180118 | C07H19/23 | AU20170279590 | CLARKE MICHAEL O'NEIL HANRAHAN | AU2017279590A1 | GILEAD SCIENCES INC | |||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07H19/12;A61K31/706;A61K45/06 | Provided are compounds of Formula I, as well as pharmaceutical compositions containing compounds of Formula I and methods for treating Orthomyxoviridae virus infections by administering these compounds. The compounds, compositions, and methods provided are particularly useful for the treatment of Human Influenza virus infections. | 20130311 | US(美国) | 20130919 | US2011230654A1;US8008264B2;US8318682B2;US8012941B2 | C07H19/12 | US201313793557 | CLARKE MICHAEL O'NEIL HANRAHAN | US2013243725A1 | GILEAD SCIENCES INC | ||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07H17/02;A61K31/706;A61K45/06 | Provided are methods for treating Orthomyxoviridue virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula I: wherein R2 is halogen. The compounds, compositions, and methods provided are particularly useful for the treatment of Human Influenza virus infections. | 20140124 | US(美国) | 20140717 | C07H17/02 | US201414163251 | CLARKE MICHAEL O'NEIL HANRAHAN;KIM CHOUNG U;LEW WILLARD | US2014200188A1 | GILEAD SCIENCES INC | |||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07H7/06;A61K9/00;A61K31/706;A61K45/06 | Provided are methods for treating Paramyxoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula I: wherein the 1′ position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Human parainfluenza and Human respiratory syncytial virus infections. | 20141222 | US(美国) | 20150423 | US2008161324A1;US2010249068A1;US8853171B2;US8012941B2;US8318682B2;US8008264B2;WO2009132135A1 | C07H7/06 | US201414579348 | MACKMAN RICHARD L;PARRISH JAY P;RAY ADRIAN S;THEODORE DOROTHY A | US2015111839A1 | GILEAD SCIENCES INC | ||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07D309/10;C07H19/00 | Provided are methods for treating Paramyxoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula (I): wherein the 1 ' position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Human parainfluenza and Human respiratory syncytial virus infections. | 20170223 | AU(澳大利亚) | 20190502 | WO2009132135A1 | C07D309/10 | AU20170201230 | MACKMAN RICHARD L;PARRISH JAY P;RAY ADRIAN S;THEODORE DOROTHY AGNES | AU2017201230B2 | GILEAD SCIENCES INC | ||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07D309/10;C07H19/00 | Provided are methods for treating Paramyxoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula (I): wherein the I 'position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Human parainfluenza and Human respiratory syncytial virus infections. | 20190723 | AU(澳大利亚) | 20190808 | C07D309/10 | AU20190208167 | MACKMAN RICHARD L;PARRISH JAY P;RAY ADRIAN S;THEODORE DOROTHY AGNES | AU2019208167A1 | GILEAD SCIENCES INC | |||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07D309/10;C07H19/00 | Provided are methods for treating Paramyxoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula (I): wherein the 1 ' position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Human parainfluenza and Human respiratory syncytial virus infections. | 20110722 | WO(世界知识产权局) | 20120126 | WO2009132135A1;WO2010002877A2;WO2008141079A1;WO2008089105A2;WO0056734A1;US4816570A;US4968788A;US5663159A;US5792756A;WO9119721A1;US6312662B1;US5458135A;US5740794A;US5775320A;US5785049A;US3906950A;US4013075A;US4069819A;US4995385A;US5522385A;US4668218A;US4667668A;US4805811A;US5388572A;US5261538A;US5544647A;US5622163A;US4955371A;US3565070A;US3361306A;US6116234A | C07D309/10 | WO2011US45102 | MACKMAN RICHARD L;PARRISH JAY P;RAY ADRIAN S;THEODORE DOROTHY AGNES | WO2012012776A1 | GILEAD SCIENCES INC;MACKMAN RICHARD L;PARRISH JAY P;RAY ADRIAN S;THEODORE DOROTHY AGNES | ||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | A61K31/706;A61K39/395;A61P31/12;C07H19/04 | Provided are methods for treating Paramyxoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula I: wherein the 1′ position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Human parainfluenza and Human respiratory syncytial virus infections. | 20110722 | US(美国) | 20120202 | US2008161324A1;WO2009132135A1 | A61K31/706 | US201113189373 | MACKMAN RICHARD L;PARRISH JAY P;RAY ADRIAN S;THEODORE DOROTHY AGNES | US2012027752A1 | MACKMAN RICHARD L;PARRISH JAY P;RAY ADRIAN S;THEODORE DOROTHY AGNES;GILEAD SCIENCES INC | ||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07D487/04;C07F9/6561 | Provided are methods for treating Paramyxoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula I: wherein the 1′ position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Human parainfluenza and Human respiratory syncytial virus infections. | 20150204 | US(美国) | 20150604 | C07D487/04 | US201514613719 | MACKMAN RICHARD L;PARRISH JAY P;RAY ADRIAN S;THEODORE DOROTHY AGNES | US2015152116A1 | GILEAD SCIENCES INC | |||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07D487/04;A61K9/00;A61K31/706;A61K45/06;C07F9/6561;C07H7/06;C07H19/04 | wherein the 1′ position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Human parainfluenza and Human respiratory syncytial virus infections. | 20180723 | US(美国) | 20190221 | C07D487/04 | US201816042085 | MACKMAN RICHARD L;PARRISH JAY P;RAY ADRIAN S;THEODORE DOROTHY AGNES | US2019055251A1 | GILEAD SCIENCES INC | |||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07D473/18;C07H19/16;A61K31/513;A61K31/52;A61K31/522;A61K31/7068;A61K31/7072;A61K31/7076;A61K31/708;A61P3/12;A61P31/12;A61P35/00;A61P35/02;C07D405/04;C07D473/30;C07D473/34;C07H19/048;C07H19/06;C07H19/067;C07H19/10;C07H19/167;C07H19/20;C07H21/04;C12Q1/68 | The disclosed invention is a composition for and a method of treating a Flaviviridae (including BVDV and HCV), Orthomyxoviridae (including Influenza A and B) or Paramyxoviridae (including RSV) infection, or conditions related to abnormal cellular proliferation, in a host, including animals, and especially humans, using a nucleoside of general formula (I)-(XXIII) or its pharmaceutically acceptable salt or prodrug. This invention also provides an effective process to quantify the viral load, and in particular BVDV, HCV or West Nile Virus load, in a host, using real-time polymerase chain reaction ("RT-PCR"). Additionally, the invention discloses probe molecules that can fluoresce proportionally to the amount of virus present in a sample. | 20130603 | US(美国) | 20140227 | US6080791A;US6348587B1;WO0191737A2 | C07D473/18 | US201313908098 | STUYVER LIEVEN;WATANABE KYOICHI | US2014057863A1 | GILEAD SCIENCES INC | ||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07H19/00;A61P31/14 | The present invention relates to novel salts and crystalline forms of (S)-2-ethylbutyl 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate for use in treating viral infections. In some embodiments, the viral infection is caused by a virus selected from the group consisting of Arenaviridae, Coronaviridae, Filoviridae, Flaviviridae, and Paramyxoviridae. | 20180427 | US(美国) | 20181206 | C07H19/00 | US201815964597 | BRAK KATRIEN;CARRA ERNEST A;HEUMANN LARS V;LARSON NATE | US2018346504A1 | GILEAD SCIENCES INC | |||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | A61P31/14;A61K31/53;C07F9/6561 | The present invention relates to novel salts and crystalline forms of (S)-2-ethylbutyl2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1- f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl) methoxy)(phenoxy)phosphoryl)amino)propanoate (Formula I) for use in treating viral infections. In some embodiments, the viral infection is caused by a virus selected from the group consisting of Arenaviridae, Coronaviridae, Fil oviridae, Fiaviviridae,and Paramyxoviridae. | 20180427 | WO(世界知识产权局) | 20181108 | US201662325419P;US201514926062A;US2015057933W | A61P31/14 | WO2018US29974 | BRAK KATRIEN;CARRA ERNEST A;HEUMANN LARS V;LARSON NATE | WO2018204198A1 | GILEAD SCIENCES INC | ||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | A61K31/08;A61K31/4178;A61K31/506;A61K45/06;C07D403/04 | The present invention is directed to compounds, methods and compositions for treating or preventing viral infections using nucleosides analogs. Specifically, the present invention provides for the design and synthesis of acyclic fleximer nucleoside analogues having increased flexibility and ability to alter their conformation structures to provide increased antiviral activity potential with the result of inhibiting several coronaviruses. | 20160128 | US(美国) | 20180118 | A61K31/08 | US201615546818 | RADTKE KATHERINE L;PETERS HANNAH L;NEYTS JOHAN;JOCHMANS DIRK;SNIJDER ERIC J | US2018015052A1 | UNIV MARYLAND;UNIV LEUVEN KATH;LEIDEN UNIV MEDICAL CENTER | |||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | A61K31/08;A61K31/4178;A61K31/506;A61K45/06;C07D403/04 | The present invention is directed to compounds, methods and compositions for treating or preventing viral infections using nucleosides analogs. Specifically, the present invention provides for the design and synthesis of acyclic fleximer nucleoside analogues having increased flexibility and ability to alter their conformation structures to provide increased antiviral activity potential with the result of inhibiting several coronaviruses. | 20180702 | US(美国) | 20181025 | A61K31/08 | US201816025284 | RADTKE KATHERINE L;PETERS HANNAH;NEYTS JOHAN;JOCHMANS DIRK;SNIJDER ERIC J | US2018303768A1 | UNIV MARYLAND | |||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | A61K31/08;A61K31/4178;A61K31/506;A61K45/06;C07D403/04 | The present invention is directed to compounds, methods and compositions for treating or preventing viral infections using nucleosides analogs. Specifically, the present invention provides for the design and synthesis of acyclic fleximer nucleoside analogues having increased flexibility and ability to alter their conformation structures to provide increased antiviral activity potential with the result of inhibiting several coronaviruses. | 20190312 | US(美国) | 20190704 | A61K31/08 | US201916299379 | RADTKE KATHERINE L;PETERS HANNAH;NEYTS JOHAN;JOCHMANS DIRK;SNIJDER ERIC J | US2019201352A1 | UNIV MARYLAND;UNIV LEUVEN KATH;LEIDEN UNIV MEDICAL CENTER | |||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | A61K31/706;A61P31/12 | Provided are methods of treating feline Coronavirus infections comprising administering a therapeutically effective amount of aza-sugar containing nucleoside analogs or pharmaceutically acceptable salts thereof. | 20180313 | WO(世界知识产权局) | 20180920 | A61K31/706 | WO2018US22166 | PERRON MICHEL JOSEPH | WO2018169946A1 | GILEAD SCIENCES INC | |||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07D307/12;A61K31/505;C07D239/10;C07D405/04 | Disclosed are halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of viral infections. Such viral infections can include tongaviridae, bunyaviridae, arenaviridae, coronaviridae, flaviviridae, picornaviridae, Eastern, Western, and Venezuelan Equine Encephalitis (EEE, WEE and VEE, respectively), Chikungunya fever (CHIK), Ebola, Influenza, RSV, and Zika virus infections. | 20190307 | WO(世界知识产权局) | 20190912 | C07D307/12 | WO2019US21168 | PAINTER GEORGE R;PERRYMAN DAVID;BLUEMLING GREGORY R | WO2019173602A1 | UNIV EMORY | |||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | A61K31/365;A61K31/381 | Infection by a Coronaviridae virus (e.g., a coronavirus) and/or illness due to a Coronaviridae virus are treated or protected against by administration of a therapeutically or prophylactically effective amount of certain nucleoside compounds and derivatives thereof, either alone or in a composition comprising the nucleoside compound or its derivative and a pharmaceutically acceptable carrier. In addition, replication of a Coronaviridae virus is inhibited by administration of the nucleoside compounds and derivatives thereof, either alone or in pharmaceutical compositions. The nucleosides are particularly suitable for use in treating or prophylaxis of an infection by the SARS virus and/or in treating or prophylaxis of SARS, and for use in inhibiting replication of the SARS virus. The nucleoside compounds and derivatives can optionally be administered in combination with other agents active against the Coronaviridae virus and/or an illness due to the virus. The nucleoside compounds are also for use in the manufacture of medicaments for the inhibition of Coronaviridae virus replication, for the treatment or prophylaxis of Coronaviridae virus infection, and/or for the treatment or prophylaxis of an illness due to a Coronaviridae virus (e.g., the SARS virus). In addition, the compounds are for use as medicaments for the inhibition of Coronaviridae virus replication, for the treatment or prophylaxis of Coronaviridae virus infection, and/or for the treatment or prophylaxis of an illness due to a Coronaviridae virus. | 20040427 | US(美国) | 20041223 | US2003050229A1;US2003060400A1;US6777395B2;US2002147160A1;US6812219B2 | A61K31/365 | US20040832945 | OLSEN DAVID B;TOMASSINI JOANNE E;MAO SHI-SHAN;CARROLL STEVEN S | US2004259934A1 | |||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07H19/04;A61K31/7052;A61P31/12;C07H19/056;C07H19/06 | Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus, with a nucleoside, a nucleotide and an analog thereof. Examples of viral infections include a respiratory syncytial viral (RSV) and influenza infection. | 20110919 | WO(世界知识产权局) | 20120329 | WO2008086042A2;EP0457326A1;WO2009067409A1;WO2007020193A2 | C07H19/04 | WO2011US52217 | BEIGELMAN LEONID;DEVAL JEROME;SMITH DAVID BERNARD;WANG GUANGYI;RAJWANSHI VIVEK KUMAR | WO2012040124A1 | ALIOS BIOPHARMA INC;BEIGELMAN LEONID;DEVAL JEROME;SMITH DAVID BERNARD;WANG GUANGYI;RAJWANSHI VIVEK KUMAR | ||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | A61K31/7068;A61K31/7072;A61K31/7076;A61K31/708 | Disclosed herein are nucleosides, nucleotides and analogs thereof of formula I, II and III, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus, with a nucleoside, a nucleotide and an analog thereof. In particular, viral infections caused by a virus selected from henipavirus, a morbillivirus, a respirovirus, a rubulavirus and a metapneumovirus. | 20130319 | NZ(新西兰) | 20161028 | A61K31/7068 | NZ20130629428 | SMITH DAVID BERNARD;DEVAL JEROME;BEIGELMAN LEONID;PRHAVC MARIJA;WANG GUANGYI | NZ629428A | ALIOS BIOPHARMA INC | |||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | A61K31/70;A01N43/04;A61K31/7056;A61K31/7068;A61K31/7072;A61K31/7076;A61K31/708;A61K31/7105;A61K45/06;C07H19/00;C07H19/04;C07H19/048;C07H19/056;C07H19/067;C07H19/073;C07H19/09;C07H19/10;C07H19/11;C07H19/167;C07H19/173;C07H19/19;C07H19/20 | Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus, with a nucleoside, a nucleotide and an analog thereof. Examples of viral infections include a respiratory syncytial viral (RSV) and influenza infection. | 20110919 | US(美国) | 20141104 | US7094768B2;US7151089B2;US7629328B2;US5449664A;US5681940A;US5712378A;US6787525B1;US7915232B2;US2003064945A1;US2003124513A1;US2004259934A1;US2006040890A1;US2007042988A1;US2007066815A1;US2008008682A1;US2008039428A1;US2008107628A1;US2008161254A1;US2008188458A1;US2009176732A1;US2009318380A1;US2010151001A1;US2010234584A1;US2010240604A1;US2010249068A1;US2010297079A1;US2010331397A1;US2011020272A1;US2012070411A1;US2012071434A1;US2012165286A1;US2013164261A1;US2013165400A1;US2013252920A1;US2013253181A1;US2013281687A1;EP0371366A1;EP0457326A1;EP2177527A1;EP2166016A1;WO9221343A1;WO9614329A1;WO9816184A2;WO9816186A2;WO9914226A2;WO0034298A1;WO0066604A2;WO02100415A2;WO03026589A2;WO03026675A1;WO03039523A2;WO03070193A2;WO03070912A2;WO03073989A2;WO03102131A2;WO2004002422A2;WO2004002999A2;WO2004003000A2;WO2004014312A2;WO2004046159A1;WO2004052906A1;WO2004062676A1;WO2004080466A1;WO2004106356A1;WO2005000864A1;WO2005020884A2;WO2005021568A2;WO2006000922A2;WO2006094347A1;WO2007005779A2;WO2007020193A2;WO2007038859A1;WO2007038860A2;WO2007113538A1;WO2008005542A2;WO2008043704A1;WO2008043791A2;WO2008071571A1;WO2008083465A1;WO2008086042A2;WO2008089105A2;WO2008095040A2;WO2008100447A2;WO2008117047A1;WO2008121634A2;WO2008124384A2;WO2008125583A1;WO2008125599A1;WO2008136815A2;WO2009009951A1;WO2009025759A1;WO2009040269A1;WO2009064848A1;WO2009067409A1;WO2009069095A2;WO2009080836A2;WO2009085267A1;WO2009086192A1;WO2009086201A1;WO2009102318A1;WO2009120991A2;WO2009132123A1 | A61K31/70 | US201113236486 | BEIGELMAN LEONID;DEVAL JEROME;SMITH DAVID BERNARD;WANG GUANGYI;RAJWANSHI VIVEK KUMAR | US8877731B2 | BEIGELMAN LEONID;DEVAL JEROME;SMITH DAVID BERNARD;WANG GUANGYI;RAJWANSHI VIVEK KUMAR;ALIOS BIOPHARMA INC | ||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07H19/20;C07H19/056;C07H19/06;C07H19/10;C07H19/16 | Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus, with a nucleoside, a nucleotide and an analog thereof. Examples of viral infections include a respiratory syncytial viral (RSV) and influenza infection. | 20141103 | US(美国) | 20150702 | US8877731B2;US8236779B2 | C07H19/20 | US201414531552 | BEIGELMAN LEONID;DEVAL JEROME;SMITH DAVID BERNARD;WANG GUANGYI;RAJWANSHI VIVEK KUMAR | US2015183819A1 | ALIOS BIOPHARMA INC | ||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07H19/06;C07H19/056;C07H19/10;C07H19/16;C07H19/20 | Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus, with a nucleoside, a nucleotide and an analog thereof. Examples of viral infections include a respiratory syncytial viral (RSV) and influenza infection. | 20160523 | US(美国) | 20160915 | C07H19/06 | US201615161821 | BEIGELMAN LEONID;DEVAL JEROME;SMITH DAVID BERNARD;WANG GUANGYI;RAJWANSHI VIVEK KUMAR | US2016264610A1 | ALIOS BIOPHARMA INC | |||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | A61K31/7115;A61K48/00;A61P3/00;A61P7/04;A61P21/04;A61P25/14;A61P35/00;C07H21/00;C07H21/04;C12N15/10;C12N15/115;C12P19/34;C12Q1/68 | It is intended to provide a process for producing a functional molecule which shows high affinities for various targets. Namely, a process for producing a functional molecule which involves the step of producing a modified oligonucleotide sequence wherein a modified nucleotide n-mer (n representing an integer) containing a modified nucleoside having a substituent transferred into a nucleoside constituting a nucleic acid is polymerized at random to give the modified oligonucleotide sequence. A preferable embodiment thereof comprises the selection step of selecting a modified nucleotide sequence having an affinity for a target from among the modified nucleotide sequences the sequence-reading out step of amplifying the modified nucleotide sequence thus selected and determining its base sequence and the translation step of translating the sequence of the modified oligonucleotide sequence having the thus determined base sequence based on the relation between at least one of 4 nucleotide n-mers and the modified nucleotide n-mer referring to a relation table showing one-to-one combinations of the 4 nucleotides. | 20030314 | WO(世界知识产权局) | 20030925 | WO9203461A1;WO9640717A1;WO9921873A2;EP1201751A1 | A61K31/7115 | WO2003JP03087 | FUJIHARA TSUYOSHI;FUJITA SHOZO;TAKEISHI SHUNSAKU | WO03078623A1 | FUJITSU LTD;FUJIHARA TSUYOSHI;FUJITA SHOZO;TAKEISHI SHUNSAKU | ||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | A61K31/7115;A61K48/00;A61P3/00;A61P7/04;A61P21/04;A61P25/14;A61P35/00;C07H21/00;C07H21/04;C12N15/10;C12N15/115;C12P19/34;C12Q1/68 | A process for producing a functional molecule includes a forming step which forms a modified nucleotide n-mer (where, n represents an integer) containing a modified nucleoside prepared by introducing a substituent into a nucleoside composing a nucleic acid and a producing step which produces a modified oligonucleotide sequence by randomly polymerizing the modified nucleotide n-mer. A preferable embodiment thereof includes a selecting step which selects a sequence having an affinity to a target from the modified oligonucleotide sequence, a determining step which amplifies the selected modified oligonucleotide sequence and determines the base sequence thereof, and a translating step which translates the sequence of the modified oligonucleotide sequence on the basis of a relation table prepared by relating at least one of 4n kinds of nucleotide n-mers, which are presented in the relation table prepared by the one-to-one combination of 4 kinds of nucleosides, to a modified nucleotide n-mer. | 20040917 | US(美国) | 20050616 | US5756291A;US6423493B1;US2002106679A1 | A61K31/7115 | US20040943150 | FUJIHARA TSUYOSHI;FUJITA SHOZO;TAKEISHI SHUNSAKU | US2005130195A1 | FUJITSU LTD | ||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | A61K31/7115;A61K48/00;A61P3/00;A61P7/04;A61P21/04;A61P25/14;A61P35/00;C07H21/00;C07H21/04;C12N15/10;C12N15/115;C12P19/34;C12Q1/68 | The object of the present invention is to provide a process for producing a functional molecule having a high affinity to various targets. Accordingly, the process for producing the functional molecule includes a producing step which produces a modified oligonucleotide sequence by polymerizing randomly a modified nucleotide n-mer (where, n represents an integer) containing a modified nucleoside prepared by introducing a substituent into a nucleoside composing a nucleic acid. An aspect preferably comprises a selecting step which selects a sequence having an affinity to a target from the modified oligonucleotide sequence, a determining step which amplifies the selected modified oligonucleotide sequence and determines the base sequence thereof, and a translating step which translates the sequence of the modified oligonucleotide sequence, of which base sequence has been determined, on the basis of a relation table prepared by relating at least one of 4 kinds of nucleotide n-mers, which are presented in the relation table prepared by the one-to-one combination of 4 kinds of nucleosides, to a modified nucleotide n-mer. | 20030314 | EP(欧洲专利局) | 20041222 | WO9205285A1;WO0024404A1;US5756291A;WO9214842A1;WO0023456A1 | A61K31/7115 | EP20030708622 | FUJIHARA TSUYOSHI;FUJITA SHOZO;TAKEISHI SHUNSAKU | EP1489171A1 | FUJITSU LTD | ||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07D311/36;C07D311/34 | PURPOSE: A dihydroxychromone derivative is provided to suppress SARS(severe acute respiratory syndrome)-coronavirus helicase activity which causes SARS. CONSTITUTION: A pharmaceutical composition for preventing and treating diseases caused by a coronavirus contains a compound of chemical formula 1 or a pharmaceutically acceptable salt, hydrate or isomer thereof as an active ingredient. The pharmaceutical composition further contains one or more pharmaceutically acceptable carriers, diluents, or excipients. The disease is SARS(severe acute respiratory syndrome). The pharmaceutical composition further contains an antiviral agent. The antiviral agent is a virus serine protease inhibitor, virus polymerase inihibitor, interferone alpha, or ribavirin. | 20090713 | KR(韩国) | 20110120 | C07D311/36 | KR20090063550 | CHONG YOU HOON;JEONG YONG JOO;LEE CHAE WOON | KR20110006083A | UNIV KONKUK IND COOP CORP | |||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | A61K31/404;A61P31/14 | FIELD: medicine, virology, pharmacy. ^ SUBSTANCE: invention proposes an agent for treatment and prophylaxis of infection caused by coronaviruses, in particular, for treatment of atypical pneumonia (SARS), and pharmaceutical composition of indicated designation based on thereof. Agent represents 1-methyl-2-phenylthiomethyl-3-carbethoxy-4-dimethylaminomethyl-5-oxybromoindole or 1-methyl-2-phenylthiomethyl-3-carbethoxy-4-dimethylaminomethyl-5-oxybromoindole monohydrate hydrochloride (arbidol) known early as an immunomodulator and preparation used against influenza viruses. Invention provides reducing accumulation of coronaviruses (on example with TOPS virus) in lung. ^ EFFECT: valuable medicinal properties of agent. ^ 2 cl, 7 tbl, 9 ex | 20040421 | RU(俄罗斯联邦) | 20050720 | A61K31/404 | RU20040111871 | GLUSHKOV R G;MAKSIMOV V A;MART JANOV V A;KHAMITOV R A;SHUSTER A M | RU2256451C1 | ||||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | A61K31/713;A61K38/21;A61P11/00;A61P31/12;A61K31/24;A61K31/4196;A61K31/7088;A61K48/00 | Avian influenza is treated with natural human alpha interferon, neuraminidase inhibitor(s) and ribavirin. Effects of influenza virus are mitigated with a dsRNA in combination with a neuraminidase influenza virus inhibitor. These two products, dsRNA, and alpha interferon, have therapeutic utility either given preventively (prophylactically) or in treatment of active disease. These unique immunological/antiviral actions, operating through immunological "cascades" ameliorates the lethal effects of viral mutation which, by causing resistance to commonly available drugs, greatly accelerates the death rate. | 20051108 | AU(澳大利亚) | 20051215 | A61K31/713 | AU20050229761 | CARTER WILLIAM A;STRAYER DAVID | AU2005229761A1 | HEMISPHERX BIOPHARMA | |||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07H19/073;A61K31/7064;A61P33/06;C07H19/067 | The present invention includes the utility of anti-viral and/or antibacterial effective amounts of 6-substituted nucleoside derivatives of formula (I) (e.g. 6-iodouridine and 6-iodouridine monophosphate) in the treatment or prevention of viral infections (e.g. Flavivridae, Bunyaviridae, or Togaviridae, or viral infections of hepatitis C, hepatitis B, herpes, influenza, HIV, polio, Coxsackie A/B, rhino, small pox, Ebola, West Nile, or corona virus) and/or bacterial infections (e.g. H. pylori, S. Aureus, B. anthracis, Mycobacterial tuberculosis, M. leprae, M. avium, P. aueruginosa, Streptococcal species, and Pneumocystis carinii). | 20061003 | AP(AP) | 20140331 | US4873228A | C07H19/073 | AP20080004436 | BELLO ANGELICA;FUJIHASHI MASAHIRO;KOTRA LAKSHMI P | AP2870A | UNIV HEALTH NETWORK | ||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07H19/10;A61K31/7068;A61K31/7072;A61K45/06;C07B59/00;C07H19/06 | The present invention is directed to compounds, compositions and methods for treating or preventing Flaviviridae family of viruses (including HCV, Yellow fever, Dengue, Chikungunya Ebola and West Nile virus), RSV, HEV, and influenza infection and cancer in human subjects or other animal hosts. | 20151030 | US(美国) | 20171123 | C07H19/10 | US201515522056 | COATS STEVEN J;AMBLARD FRANCK;GARNIER-AMBLARD ETHEL;SCHINAZI RAYMOND F | US2017334941A1 | COCRYSTAL PHARMA INC;UNIV EMORY | |||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | A61K47/48;C07F9/6512;A61K31/662;A61P3/14;A61P9/08;A61P19/00;A61P19/10;A61P31/00;A61P31/12;A61P35/00;A61P43/00;C07F9/38;C07F9/40;C07F9/6561;C07F9/6574;C07H19/10 | The present invention relates to phosphonate ester compounds formed by the covalent linking of a phosphonate selected from (a) cidofovir or tenofovir (b) an antiviral nucleoside phosphonate or an antiproliferative nucleoside phosphonate and (c) a derivative of cytosine arabinoside, gemcitabine, 5-fluorodeoxyuridine riboside, 2-chlorodeoxyadenosine, fludarabine or 1-beta-D-arabinofuranoxyl-guanine to an alkylpropanediol. The compounds are used in the preparation of medicaments for treating a viral disease in a subject in need thereof, wherein said viral disease is selected from the human immunodeficiency virus, influenza, the herpes simplex virus, the human herpes virus, the cytomegalovirus, the hepatitis B and C virus, the Epstein-Barr virus, the varicella zoster virus, the orthopox virus, the ebola virus and the papilloma virus. | 20001204 | EP(欧洲专利局) | 20080423 | EP0632048A1;WO9838202A1;EP0479640A2 | A61K47/48 | EP20080001408 | HOSTETLER KARL Y;KINI GANESH D;BEADLE JAMES R | EP1914237A2 | UNIV CALIFORNIA AT SAN DIEGO | ||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | A61K31/7042;A61K31/7072;A61K31/513;A61P31/00;A61P31/04;A61P31/06;A61P31/14;A61P31/16;A61P31/18 | The present invention includes the utility of anti-viral and/or antibacterial effective amounts of 6-substituted nucleoside derivatives of formula (I) (e.g. 6-iodouridine and 6-iodouridine monophosphate) in the treatment or prevention of viral infections (e.g. Flavivridae, Bunyaviridae, or Togaviridae, or viral infections of hepatitis C, hepatitis B, herpes, influenza, HIV, polio, Coxsackie A/B, rhino, small pox, Ebola, West Nile, or corona virus) and/or bacterial infections (e.g. H. pylori, S. Aureus, B. anthracis, Mycobacterial tuberculosis, M. leprae, M. avium, P. aueruginosa, Streptococcal species, and Pneumocystis carinii). | 20061003 | US(美国) | 20100408 | A61K31/7042 | US20060089100 | KOTRA LAKSHMI P;PAI EMIL F | US2010087388A1 | KOTRA LAKSHMI P;PAI EMIL F | |||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07H19/073;A61K31/7064;A61P33/06;C07H19/067 | The present invention includes the utility of anti-viral and/or antibacterial effective amounts of 6-substituted nucleoside derivatives of formula (I) (e.g. 6-iodouridine and 6-iodouridine monophosphate) in the treatment or prevention of viral infections (e.g. Flavivridae, Bunyaviridae, or Togaviridae, or viral infections of hepatitis C, hepatitis B, herpes, influenza, HIV, polio, Coxsackie A/B, rhino, small pox, Ebola, West Nile, or corona virus) and/or bacterial infections (e.g. H. pylori, S. Aureus, B. anthracis, Mycobacterial tuberculosis, M. leprae, M. avium, P. aueruginosa, Streptococcal species, and Pneumocystis carinii). | 20061003 | EP(欧洲专利局) | 20080618 | C07H19/073 | EP20060790781 | KOTRA LAKSHMI P;PAI EMIL F;BELLO ANGELICA M;FUJIHASHI MASAHIRO | EP1931691A1 | UNIV HEALTH NETWORK | |||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07H19/173;A61K31/7052;A61K31/706;A61K31/7076;A61K31/708;A61P31/12;A61P31/18;A61P31/20;A61P35/00;C07H19/04;C07H19/23 | The present disclosure provides nucleoside analogs of Formula (I) or (II). The nucleoside analogs may show multiple tautomerism and may increase the mutation of an RNA and/or DNA (be mutagenic) of a virus or cancer cell. The multiple tautomerism and mutagenesis of the nucleoside analogs may be adjusted by substituting the nucleoside analogs with one or more electron-donating groups and/or electron-withdrawing groups to increase or decrease the pK a (e.g., to a pK a between 5.5 or 8.5). The present disclosure also provides pharmaceutical compositions and kits including the nucleoside analogs and methods of treating a viral infection (e.g., influenza, HIV infection, or hepatitis) or cancer using the nucleoside analogs, pharmaceutical compositions, or kits. | 20160128 | WO(世界知识产权局) | 20160804 | US2014206639A1 | C07H19/173 | WO2016US15456 | ESSIGMANN JOHN M;TOKMAKOFF ANDREI;FEDELES BOGDAN I;SINGH VIPENDER;PENG CHUNTE | WO2016123397A2 | MASSACHUSETTS INST TECHNOLOGY | ||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07H19/12;C12Q1/68;G01N21/3577;G01N33/15 | The present disclosure provides nucleoside analogs of Formula (I) or (II). The nucleoside analogs are expected to show multiple tautomerism and may increase the mutation of an RNA and/or DNA (be mutagenic) of a virus or cancer cell. The multiple tautomerism and mutagenesis of the nucleoside analogs may be adjusted by substituting the nucleoside analogs with one or more electron-donating groups and/or electron-withdrawing groups to increase or decrease the pKa (e.g., to a pKa between 5.5 or 8.5). The present disclosure also provides pharmaceutical compositions and kits including the nucleoside analogs and methods of treating a viral infection (e.g., influenza, HIV infection, or hepatitis) or cancer using the nucleoside analogs, pharmaceutical compositions, or kits. | 20160128 | US(美国) | 20160804 | C07H19/12 | US201615009628 | ESSIGMANN JOHN M;TOKMAKOFF ANDREI;FEDELES BOGDAN I;SINGH VIPENDER;PENG CHUNTE | US2016222050A1 | MASSACHUSETTS INST TECHNOLOGY | |||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07H19/12;A61K31/7052;A61K31/706;A61K31/7064;A61K31/7068;A61K31/7076;A61K31/708;C07H19/04;C07H19/173;C07H19/23;C12Q1/68;G01N21/3577;G01N33/15 | The present disclosure provides nucleoside analogs of Formula (I) or (II). The nucleoside analogs are expected to show multiple tautomerism and may increase the mutation of an RNA and/or DNA (be mutagenic) of a virus or cancer cell. The multiple tautomerism and mutagenesis of the nucleoside analogs may be adjusted by substituting the nucleoside analogs with one or more electron-donating groups and/or electron-withdrawing groups to increase or decrease the pKa (e.g., to a pKa between 5.5 or 8.5). The present disclosure also provides pharmaceutical compositions and kits including the nucleoside analogs and methods of treating a viral infection (e.g., influenza, HIV infection, or hepatitis) or cancer using the nucleoside analogs, pharmaceutical compositions, or kits. | 20170706 | US(美国) | 20171102 | C07H19/12 | US201715642402 | ESSIGMANN JOHN M;TOKMAKOFF ANDREI;FEDELES BOGDAN I;SINGH VIPENDER;PENG CHUNTE | US2017313736A1 | MASSACHUSETTS INST TECHNOLOGY | |||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07H19/10;A61K9/00;A61K9/14;A61K31/7072;A61K45/06;C07H19/06 | The present invention is directed to compounds, compositions and methods for treating or preventing Flaviviridae family of viruses (including HCV, Yellow fever, Dengue, Chikungunya and West Nile virus), RSV, HEV, and influenza infection and cancer in human subjects or other animal hosts. | 20160427 | US(美国) | 20170817 | C07H19/10 | US201615139924 | COATS STEVEN J;AMBLARD FRANCK;MENGSHETTI SEEMA;LI HAO;SCHINAZI RAYMOND F | US2017233428A1 | COCRYSTAL PHARMA INC;UNIV EMORY | |||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07H19/06;A61K31/7068;A61K31/7076;A61P31/12;A61P31/16;A61P35/00;C07H19/16 | The present invention is directed to compounds, compositions and methods for treating or preventing Flaviviridae family of viruses (including HCV, Yellow fever, Dengue, Chikungunya and West Nile virus), RSV and influenza infection and cancer in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment or prevention of HCV infection. | 20150424 | WO(世界知识产权局) | 20151029 | WO2008121634A2;WO2010080878A1 | C07H19/06 | WO2015US27630 | COATS STEVEN J;ZHOU SHAOMAN;AMBLARD FRANCK;SCHINAZI RAYMOND F;KHALIL AHMED | WO2015164812A1 | COCRYSTAL PHARMA INC;UNIV EMORY | ||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07H19/207;A61K31/706;A61K31/7068;A61K31/7072;A61K31/7076;A61K45/06;C07H19/10;C07H19/12;C07H19/14 | The present invention is directed to compounds, compositions and methods for treating or preventing Flaviviridae family of viruses (including HCV, Yellow fever, Dengue, Chikungunya and West Nile virus), RSV and influenza infection and cancer in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment or prevention of HCV infection. | 20150424 | US(美国) | 20170209 | C07H19/207 | US201515305287 | COATS STEVEN J;ZHOU SHAOMAN;AMBLARD FRANCK;SCHINAZI RAYMOND F;KHALIL AHMED | US2017037078A1 | COCRYSTAL PHARMA INC;UNIV EMORY | |||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07H19/10;A61K31/712;A61K38/21;A61P31/12;A61P35/00;C07H19/067;C07H19/167;C07H19/20 | The present invention is directed to compounds, compositions and methods for treating or preventing Flaviviridae family of viruses (including HCV, Yellow fever, Dengue, Chikungunya Ebola and West Nile virus), RSV, HEV, and influenza infection and cancer in human subjects or other animal hosts. | 20151030 | WO(世界知识产权局) | 20160506 | WO2013009735A1;WO2009132123A1;WO2005012327A2;US2012070411A1;WO2015081297A1;WO2015081133A2;WO2015056213A1 | C07H19/10 | WO2015US58194 | COATS STEVEN J;AMBLARD FRANCK;GARNIER-AMBLARD ETHEL;SCHINAZI RAYMOND F | WO2016069975A1 | COCRYSTAL PHARMA INC;UNIV EMORY | ||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07H19/056;A61K31/7056;A61P31/22 | FIELD: biotechnology.SUBSTANCE: invention relates to new antiviral derivatives of general formula:,where R is selected from H, CH, CH(CH), Ph, as well as to a process for their preparation that can be used in the pharmaceutical industry. The proposed production method involves introduction of isopropylidene and triphenylmethyl protecting groups into the glycosidic portion of ribavirin, dehydration of the carboxamide group into amidoxime, preparation of an O-acylated derivative with an amidoxime moiety followed by intramolecular cyclization to obtain a glycosidically protected ribavirin analogue having a 5-substituted-1,2,4-oxadiazole fragment at the 3rd position of 1,2,4-triazole, and subsequent removal of the isopropylidene and trimethylphenyl protecting groups.EFFECT: new compounds effective against herpes simplex virus type 1, influenza A virus and hepatitis C virus, as well as an effective way of their preparation, are proposed.3 cl, 12 ex, 6 dwg | 20161208 | RU(俄罗斯联邦) | 20170829 | C07H19/056 | RU20160148156 | CHUDINOV MIKHAIL VASILEVICH;ZHURILO NIKOLAJ ILICH;MATVEEV ANDREJ VALEREVICH | RU2629360C1 | FED GOSUDARSTVENNOE BYUDZHETNOE OBRAZOVATELNOE UCHREZHDENIE VYSSHEGO OBRAZOVANIYA MOSKOVSKIJ TEKH UN | |||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | A61K31/14;A61K31/21;A61K31/216;A61P31/00;A61P31/12 | The use of a compound of general formula (1) in the treatment of diseases caused by viral infection. Examples of such anti-viral agents are Benzeneacetic acid 2-(diethylamino)ethyl ester (2) and 2-(Diethylamino)ethyl-2-phenylethanoate (3). These anti-viral agents may be used on their own or they may be used in combination with other anti-viral agents, such as ribavirin. It may also be administered in combination with other agents that reduce possible side-effects during treatment. It may be administered as a tablet or as an infusion. Compounds (2) and (3) were shown to have an effect on the growth of influenza A virus in MDCK cells. | 19990318 | GB(英国) | 20000920 | EP0763754A2 | A61K31/14 | GB19990006211 | GARNETT DAVID JOHN | GB2347858A | LOVESGROVE RES LTD | ||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | A61K31/7076;A61K31/708;A61K31/7084;A61K31/7088 | PURPOSE: A base, a nucleoside, or a nucleotide effectively is provided to suppress virus replication with less side effects and to be used as an antiviral pharmaceutical composition. CONSTITUTION: An antiviral pharmaceutical composition contains one or more selected from the group consisting of adenine, guanine, uracil, cytosine, adenosine, guanosine, uridine, cytidine, adenosine biphosphate, and adenosine triphosphate. Rhinovirus is selected among rhinovirus type 2, 3, 14, 15, and 40. Enterovirus is enterovirus type 71. A pharmaceutical composition for anti-influenza virus contains adenosine and/or adenine as active ingredients. The influenza virus is influenza virus type A. | 20111122 | KR(韩国) | 20130530 | US4046879A;EP1000622A2;KR20040054775A | A61K31/7076 | KR20110122550 | KWON DUR HAN;SONG JAE HYUNG;OH SEI RYANG;LEE HYEONG KYU;EUKHTAIVAN GANSUKH | KR20130056784A | KOREA RES INST OF BIOSCIENCE | ||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | A61K31/405;A61K31/13;A61K31/196;A61K31/215;A61K31/351;A61K31/7056;A61P31/12 | The invention relates to medicine, in particular to searching and developing novel medicinal agents for treating and preventing viral infections, mainly influenza viruses. The aim of said invention is to develop more efficient and low toxic medicinal agents by combining arbidol and the analogs thereof with a preparation exhibiting another mechanism of action. Said combinations enhances the efficiency of the preparation small doses and makes it possible to reduce the probability of side effects and appearance of virus resistant strain by reducing the dose. The result is attained by the combined use of arbidol and the analogies thereof with at least one type of preparation selected from the following group of antiviral preparations: ribavirin, zanamivirin, oseltavirin, peramirin, amantadin or remantadin. | 20051228 | WO(世界知识产权局) | 20070705 | RU2008004C1;RU2262350C2;US2004062801A1 | A61K31/405 | WO2005RU00677 | LENEVA IRINA ANATOLIEVNA | WO2007075102A1 | ZAKRYTOE AKTSIONERNOE OBSCHEST;LENEVA IRINA ANATOLIEVNA | ||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | A61K31/7056;A61K38/21;A61P31/14 | The invention relates to antimicrobial agents and antibodies and compositions comprising such agents and antibodies to treat and/or prevent respiratory and related diseases, in particular those caused by human metapneumovirus. Provided is a method for treating or preventing respiratory tract infections in a subject infected with a mammalian MPV, said method comprising administering a nucleoside analog, preferably Ribavirin or a derivative thereof, and an antimicrobial neutralising antibody, preferably an anti-hMPV antibody to said subject, and use of said nucleoside analog and antimicrobial neutralising antibody for the manufacture of a medicament for treating or preventing respiratory tract infections in a subject infected with a mammalian MPV. | 20040503 | WO(世界知识产权局) | 20041111 | WO02057302A2 | A61K31/7056 | WO2004NL00293 | MAERTZDORF JEROEN;SIMON JAMES HENRY MATTHEW | WO2004096241A1 | VIRONOVATIVE BV;MAERTZDORF JEROEN;SIMON JAMES HENRY MATTHEW | ||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | A61K31/4745 | Methods to stimulate host immune system against viral infections are disclosed. Methods to stimulate immune response of a virally, influenza or cancer infected individual through an immunomodifier such as a non-nucleoside imidazoquinolinamine (heterocyclic amine) are disclosed. | 20060419 | WO(世界知识产权局) | 20061026 | US2004136917A1;US2004067953A1 | A61K31/4745 | WO2006US14803 | MANDREA EUGENE | WO2006113835A2 | MANDREA EUGENE | ||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | A61K31/4745 | Methods to stimulate host immune system against viral infections are disclosed. Methods to stimulate immune response of a virally, influenza or cancer infected individual through an immunomodifier such as a non-nucleoside imidazoquinolinamine (heterocyclic amine) are disclosed. | 20051221 | US(美国) | 20060817 | US6039969A;US6361769B1;US2004067953A1;US6569435B1;US6890904B1;US6245776B1;US6576757B1;US2003139364A1;US2004136917A1;US3608065A;US6147086A;US6491940B1 | A61K31/4745 | US20050318659 | MANDREA EUGENE | US2006183767A1 | MANDREA EUGENE | ||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | A61K9/12;A61K31/708;A61K38/44 | The present invention is a novel method using a MegaRibavirin aerosol or a MegaRibavirin combination of therapeutics for the treatment of viral disease particularly the pandemic influenza strains ??swine?? 2009 H1N1 and H5N1. This invention utilizes Ribavirin in an aerosol Mega Dose (61-161 mg/ml) alone or combined with or without other antivirals, a perfluorocarbon emulsion and anti-inflammatory/anti-oxidants. Where applicable, the perfluorocarbon emulsion may dissolve these agents enabling a depot effect and possible protracted delivery. In addition perfluorocarbon emulsions have the possible added benefit of oxygen carrying capacity and alveolar nitric oxide sequestration, which may reduce peroxynitrite formation and decrease Influenza severity. | 20090521 | US(美国) | 20101125 | US4649911A;US2006134186A1;US5049388A | A61K9/12 | US20090454663 | MCLEAY MATTHEW T | US2010297033A1 | MCLEAY MATTHEW T | ||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | A61K31/352;A61P31/12;A61P31/16;A61P31/22 | PROBLEM TO BE SOLVED: To provide an antiviral agent which has a high antiviral activity against a drug-resistance virus having resistance characteristics to well-known antiviral agents (such as Oseltamivir, Amantadine, Ganciclovir, etc.) and has a low side effect (cell toxicity). SOLUTION: The antiviral agent against the drug-resistance virus includes tricine [5,7,4'-trihydroxy-3',5'-dimethoxyflavone(4',5,7-trihydroxy-3',5'-dimethoxyflavone)(tricin)] as the effective component. Preferably, the drug-resistance virus is influenza virus, cytomegalovirus, or herpesvirus. COPYRIGHT: (C)2011,JPO&INPIT | 20090428 | JP(日本) | 20101111 | WO2008123102A1 | A61K31/352 | JP20090109646 | MURAYAMA TSUGIYA;AKUZAWA KAZUHIKO;WATANABE KUNITOMO;KOKETSU MAMORU;NINOMIYA MASAYUKI;TSUCHIDA YUZO;TSUCHIDA KOTARO;SAKURAI DAISUKE;KAWABE MITSURO;ONOGI MANABU | JP2010254649A | TSUCHIDA YUZO | ||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07D473/00;C12N7/00 | The novel nucleoside analogue 9-[1-(1,3-diacetoxy-2-propoxy)-2-acetoxy]ethylguanine has the effect of stimulating the rate of growth of certain viruses, particularly influenza viruses, so that culturing virally infected cells in the presence of this compound substantially decreases the time required for diagnosis and typing of the virus, ready for administration of appropriate anti viral measures. | 19830218 | US(美国) | 19840717 | US4347360A | C07D473/00 | US19830467900 | OGILVIE KELVIN K | US4460690A | ENS BIO LOGICALS INC | ||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07H19/207;C07H19/06 | The application discloses nucleoside derivatives of Formula I as inhibitors of Influenza RNA replication. In particular, the application discloses the use of purine and pyrimidine nucleoside derivatives of Formula I as inhibitors of Influenza RNA replication and pharmaceutical compositions containing such compounds. | 20150206 | WO(世界知识产权局) | 20150813 | C07H19/207 | WO2015US14762 | SMITH MARK;KLUMPP KLAUS G | WO2015120237A2 | RIBOSCIENCE LLC | |||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07H19/207;A61K31/7068;A61K31/7072;A61K31/7076;A61K31/708;A61K45/06;C07H19/06;C07H19/10;C07H19/16 | The application discloses nucleoside derivatives of Formula I as inhibitors of Influenza RNA replication. In particular, the application discloses the use of purine and pyrimidine nucleoside derivatives of Formula I as inhibitors of Influenza RNA replication and pharmaceutical compositions containing such compounds. | 20150206 | US(美国) | 20150813 | US2015011497A1 | C07H19/207 | US201514615928 | SMITH MARK;KLUMPP KLAUS G | US2015225441A1 | RIBOSCIENCE LLC | ||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07H7/06;A61K31/7068;A61K31/7072;A61K31/7076;A61K31/708;A61K45/06;C07H19/06;C07H19/10;C07H19/16;C07H19/213 | The application discloses nucleoside derivatives of Formula I as inhibitors of Influenza RNA replication. In particular, the application discloses the use of purine and pyrimidine nucleoside derivatives of Formula I as inhibitors of Influenza RNA replication and pharmaceutical compositions containing such compounds. | 20160620 | US(美国) | 20181009 | US9370569B2;US2015011497A1;US5192749A;US7105499B2;US2003087873A1;US2004229840A1;US2010003213A1;US2013165400A1;US2013243725A1;US2013315868A1;US2014178338A1;US2014179627A1;US2014179910A1;US2015051167A1;WO2012037038A1;WO2012040124A1;WO2013096679A1;WO2013138236A1;WO2014100505A1;WO2014209979A1;WO2015054465A1 | C07H7/06 | US201615187014 | SMITH MARK;KLUMPP KLAUS G | US10092649B2 | RIBOSCIENCE LLC | ||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07D473/18;A61K31/513;A61K31/52;A61K31/522;A61K31/7068;A61K31/7072;A61K31/7076;A61K31/708;A61P3/12;A61P31/12;A61P35/00;A61P35/02;C07D405/04;C07D473/30;C07D473/34;C07H19/048;C07H19/06;C07H19/067;C07H19/10;C07H19/16;C07H19/167;C07H19/20;C07H21/04;C12Q1/68 | The disclosed invention is a composition for and a method of treating a Flaviviridae (including BVDV and HCV), Orthomyxoviridae (including Influenza A and B) or Paramyxoviridae (including RSV) infection, or conditions related to abnormal cellular proliferation, in a host, including animals, and especially humans, using a nucleoside of general formula (I)-(XXIII) or its pharmaceutically acceptable salt or prodrug. This invention also provides an effective process to quantify the viral load, and in particular BVDV, HCV or West Nile Virus load, in a host, using real-time polymerase chain reaction ("RT-PCR"). Additionally, the invention discloses probe molecules that can fluoresce proportionally to the amount of virus present in a sample. | 20011018 | US(美国) | 20030508 | US5886162A;US5512671A;US4666892A;US5905070A;US2004110718A1;US4211773A;US5034518A;US5446029A;US5246924A;US5808040A;US5565438A;US5567688A;US6812219B2;US5587362A;US5703058A;US7307065B2 | C07D473/18 | US20010045292 | STUYVER LIEVEN;WATANABE KYOICHI | US2003087873A1 | |||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | A61K31/7076;C07D473/18;A61K31/513;A61K31/52;A61K31/522;A61K31/7064;A61K31/7068;A61K31/7072;A61K31/708;A61P3/12;A61P31/12;A61P31/14;A61P35/00;A61P35/02;C07D405/04;C07D473/30;C07D473/34;C07H19/048;C07H19/06;C07H19/067;C07H19/10;C07H19/16;C07H19/167;C07H19/20;C07H21/04;C12Q1/68 | The disclosed invention is a composition for and a method of treating a Flaviviridae (including BVDV and HCV), Orthomyxoviridae (including Influenza A and B) or Paramyxoviridae (including RSV) infection, or conditions related to abnormal cellular proliferation, in a host, including animals, and especially humans, using a nucleoside of general formula (I)-(XXIII) or its pharmaceutically acceptable salt or prodrug. This invention also provides an effective process to quantify the viral load, and in particular BVDV, HCV or West Nile Virus load, in a host, using real-time polymerase chain reaction (??RT-PCR??). Additionally, the invention discloses probe molecules that can fluoresce proportionally to the amount of virus present in a sample. | 20100805 | US(美国) | 20111103 | US6812219B2 | A61K31/7076 | US20100805563 | STUYVER LIEVEN;WATANABE KYOICHI | US2011269707A1 | PHARMASSET INC | ||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07D473/18;A61K31/513;A61K31/52;A61K31/522;A61K31/7068;A61K31/7072;A61K31/7076;A61K31/708;A61P3/12;A61P31/12;A61P35/00;A61P35/02;C07D405/04;C07D473/30;C07D473/34;C07H19/048;C07H19/06;C07H19/067;C07H19/10;C07H19/16;C07H19/167;C07H19/20;C07H21/04;C12Q1/68 | CANRPonb\DCC\KXG\4371196_ LDOC-416/2"12 The disclosed invention is a composition for and a method of treating a Flaviviridae (including BVDV and HCV), Orthomyxoviridae (including Influenza A and B) or Paramyxoviridae (including RSV) infection, or conditions related to abnormal cellular proliferation, in a host, including animals, and especially humans, using a nucleoside of 5 general formula (I)-(XXIII) or its pharmaceutically acceptable salt or prodrug. This invention also provides an effective process to quantify the viral load, and in particular BVDV, HCV or West Nile Virus load, in a host, using real-time polymerase chain reaction ("TR-PCR"). Additionally, the invention discloses probe molecules that can fluoresce proportionally to the amount of virus present in a sample. | 20120604 | AU(澳大利亚) | 20120621 | C07D473/18 | AU20120203287 | STUYVER LIEVEN;WATANABE KYOICHI A | AU2012203287A1 | PHARMASSET INC | |||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07D473/18;A61K31/513;A61K31/52;A61K31/522;A61K31/7068;A61K31/7072;A61K31/7076;A61K31/708;A61P3/12;A61P31/12;A61P35/00;A61P35/02;C07D405/04;C07D473/30;C07D473/34;C07H19/048;C07H19/06;C07H19/067;C07H19/10;C07H19/16;C07H19/167;C07H19/20;C07H21/04;C12Q1/68 | The disclosed invention is a composition for and a method of treating a Flaviviridae (including BVDV and HCV), Orthomyxoviridae (including Influenza A and B) or Paramyxoviridae (including RSV) infection, or conditions related to abnormal cellular proliferation, in a host, including animals, and especially humans, using a nucleoside of general formula (I)-(XXIII) or its pharmaceutically acceptable salt or prodrug. This invention also provides an effective process to quantify the viral load, and in particular BVDV, HCV or West Nile Virus load, in a host, using real-time polymerase chain reaction ("TR-PCR"). Additionally, the invention discloses probe molecules that can fluoresce proportionally to the amount of virus present in a sample. | 20011018 | WO(世界知识产权局) | 20040219 | WO9818324A1;WO0160315A2;WO0218404A2 | C07D473/18 | WO2001US46113 | STUYVER LIEVEN;WATANABE KYOICHI A | WO0232920A3 | PHARMASSET LTD;STUYVER LIEVEN;WATANABE KYOICHI A | ||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | A61K31/40;A61K31/403;A61K31/404;A61P31/12;A61P37/00;A61P37/04;A61P43/00;C07D209/42 | A new substance is disclosed: ethyl ester-6-bromine-5-hydroxy-4-dimethylaminomethyl-1-methyl-2-phenylthiom ethyl indole-3-carboxylic acid hydrochloride monohydrate has formula (I). A method of obtaining said substance consists in treating the ethyl ester 5-acetoxy-1,2-dimethyl indole-3-carboxylic acid with a bromating agent in the medium of an inert organic solvent at boiling temperature, subjecting the obtained ethyl ester 5-acetoxy-6-bromine-2-bromo-methyl-1-methyl indole-3-carboxylic acid to interaction with thiophenol in the presence of a hydroxide of an alkaline metal or its alcoholate in the medium of an organic solvent, subjecting the obtained ethyl ester 6-bromine-5-hydroxy-1-methyl-2-phenylthiomethyl indole-3-carboxylic acid to interaction with an aminomethylating agent in the medium of an organic solvent at a temperature from 65 DEG C to the boiling point of the reaction mixture. Then the desired product is extracted from the obtained base, the ethyl ester 6-bromine-5-hydroxy-4-dimethylaminomethyl-1-methyl-2-phenylthiomethyl indole-3-carboxylic acid. The claimed substance is an active agent in a pharmaceutical preparation of antiviral, interferon inducing and immunomodulating action. | 19890112 | WO(世界知识产权局) | 19900726 | WO8805432A1;US4619942A;US4215137A;US4124702A;WO8706227A2 | A61K31/40 | WO1988SU00272 | TROFIMOV FEDOR ALEXANDROVICH;TSYSHKOVA NINA GAVRILOVNA;BOGDANOVA NADEZHDA SERGEEVNA;NIKOLAEVA IRINA SERGEEVNA;ZOTOVA SVETLANA ALEXEEVNA;SAKHASCHIK ZINAIDA MIKHAILOVNA;SVIRINA EVGENIA ALEXANDROVNA;FOMINA ALLA NIKOLAEVNA;PADEISKAYA ELENA NIKOLAEVNA;ZLYDNIKOV DMITRY MIKHAILOVICH;KUBAR OLGA IOSIFOVNA;SHVETSOVA EVGENIA GEORGIEVNA;BRYANTSEVA ELENA ALEXEEVNA;PETERS VALENTINA VASILIEVNA;KUTCHAK SVETLANA NIKOLAEVNA;KONOPLYANNIKOV ANATOLY GEORGIE | WO9008135A1 | GRINEVA GALINA VASILIEVNA & LF;PERSHINA ELLINA GRIGORIEVNA &;VNI KHIM FARMATS;NII MED RADI;LE NII EPID | ||
| 治疗用药 -> 化学药 -> 抑制病毒核酸复制 | C07D309/10;C07H19/00 | Provided are methods for treating Paramyxoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula (I): wherein the 1 ' position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Human parainfluenza and Human respiratory syncytial virus infections. | 20110722 | WO(世界知识产权局) | 20120126 | WO2009132135A1;WO2010002877A2;WO2008141079A1;WO2008089105A2;WO0056734A1;US4816570A;US4968788A;US5663159A;US5792756A;WO9119721A1;US6312662B1;US5458135A;US5740794A;US5775320A;US5785049A;US3906950A;US4013075A;US4069819A;US4995385A;US5522385A;US4668218A;US4667668A;US4805811A;US5388572A;US5261538A;US5544647A;US5622163A;US4955371A;US3565070A;US3361306A;US6116234A | C07D309/10 | WO2011US45102 | MACKMAN RICHARD L;PARRISH JAY P;RAY ADRIAN S;THEODORE DOROTHY AGNES | WO2012012776A1 | GILEAD SCIENCES INC;MACKMAN RICHARD L;PARRISH JAY P;RAY ADRIAN S;THEODORE DOROTHY AGNES | ||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | A61K31/472;A61P31/12;C07D217/26 | It is intended to provide an anti-coronavirus drug containing as the active ingredient a compound typified by nelfinavir or its pharmaceutically acceptable salt an anti-SARS drug containing the anti-coronavirus drug as the active ingredient and a method of treating SARS by using the anti-SARS drug. | 20040714 | WO(世界知识产权局) | 20050120 | JPH0950143A | A61K31/472 | WO2004JP10352 | FUJII NOBUTAKA;YAMAMOTO NAOKI | WO2005004868A1 | FUJII NOBUTAKA;YAMAMOTO NAOKI | ||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | A61K31/472;A61P31/12;C07D217/26 | The present invention provides an anti-coronavirus agent including as an active ingredient as exemplified by nelfinavir and salts thereof, an anti-SARS agent including the anti-coronavirus agent, and a method of treating SARS using the anti-SARS agent. | 20040714 | EP(欧洲专利局) | 20060503 | WO2004108151A1;WO02089835A2 | A61K31/472 | EP20040747768 | FUJII NOBUTAKA;YAMAMOTO NAOKI | EP1652525A1 | ARIGEN INC | ||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | A61K31/47;A61K31/426;A61K31/505;A61P31/18 | The invention includes methods, compositions, and kits useful for treating a viral infection by coadministering 6-(3-chloro-2-fluorobenzyl)-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof, with lopinavir or a pharmaceutically acceptable salt thereof. | 20080626 | UAA(UAA) | 20131210 | A61K31/47 | UAA200913904 | KEARNEY BRIAN P;MATHIAS ANITA A | UA103881C2 | GILEAD SCIENCES INC | |||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | C07D403/12;A61K31/337;A61K31/4155;A61K31/495;A61K31/504;A61K31/506;A61K31/5365;C07C243/28;C07C275/16;C07D401/12;C07D405/14;C07D471/08;C07D487/08;C07D487/10;C07D491/04 | The invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of Formula I, processes for preparing compounds of Formula I, the compound of formula (I) for use in therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS symptoms in a mammal using compounds of Formula I. Preferred compounds are N-[(2S) -1-[2-[(2S,3S)-2-hydroxy-3-[[(2S)-2-(methoxycarbonylamino) -3,3-dimethylbutanoyl]amino]-4-phenylbutyl]-2-[(phenyl) methyl]hydrazinyl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate atazanavir (ATV) analogues substituted by several heterocycles, such as e.g. pyrazole (Rl) e.g. oxetane (substituent of X2) e.g. pyridine or pyrimidine (X1) e.g. piperazine or 3,8-diazabicyclo[3.2.1]octan (X2). | 20180205 | WO(世界知识产权局) | 20180809 | C07D403/12 | WO2018US16893 | BACON ELIZABETH M;CHIN ELBERT;COTTELL JEROMY J;KATANA ASHLEY ANNE;KATO DARRYL;LINK JOHN O;SHAPIRO NATHAN;TREJO MARTIN TERESA ALEJANDRA;YANG ZHENG-YU | WO2018145021A1 | GILEAD SCIENCES INC | |||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | A61K31/426;A61K31/47;A61P31/18 | The invention provides methods for improving the pharmacokinetics of an HIV integrase inhibiting compound by administering food and/or ritonavir or a pharmaceutically acceptable salt thereof with the HIV integrase inhibitor. | 20061229 | WO(世界知识产权局) | 20070712 | WO2004067531A1;WO2004101512A2;EP1564210A1;WO2005112930A1;WO2005113508A1;US6541515B2;WO9414436A1;US5567823A;US5541206A;US5635523A;US5648497A;US5674882A;US5846987A;US5886036A;US6037157A;US6703403B2;US2005239819A1;US2004167124A1;US2005288326A1 | A61K31/426 | WO2006US49668 | KEARNEY BRIAN P;KAKEE ATSUYUKI;KAWAGUCHI ISAO | WO2007079260A1 | GILEAD SCIENCES INC;JAPAN TOBACCO INC;KEARNEY BRIAN P;KAKEE ATSUYUKI;KAWAGUCHI ISAO | ||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | A61K31/675;A61K31/513;A61K31/5377;A61K31/635;A61P31/18 | The disclosure is directed to methods of treating subjects infected with HIV, once daily, with single unit dosage forms that include darunavir (or a hydrate or solvate thereof), cobicistat, emtricitabine, and a tenofovir prodrug, or salt thereof. | 20180719 | US(美国) | 20190124 | A61K31/675 | US201816040324 | BOVEN KATIA;DE SMEDT GOEDELE;DRIESEN REGINA;HENRIST DOMINIEK;KAUWENBERGHS GREET;MATHUR SANDEEP;MCCALLISTER SCOTT;MERTENS ROEL;NETTLES RICHARD;OPSOMER MAGDA;PYRZ WILLIAM;ZIA VAHID | US2019022113A1 | JANSSEN SCIENCES IRELAND UC;GILEAD SCIENCES INC | |||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | A61K31/47 | The invention provides methods for improving the pharmacokinetics of an HIV integrase inhibiting compound by administering food and/or ritonavir or a pharmaceutically acceptable salt thereof with the HIV integrase inhibitor. | 20061229 | US(美国) | 20090917 | US2006019906A1;US2006030710A1;US7176220B2;US5886036A;US6037157A;US6703403B2;US2002045658A1;US6541515B2;US5635823A;US6407128B1;US5541206A;US5648497A;US2004167124A1;US2006217413A1;US2007219243A1;US5567523A;US5674882A;US2005239819A1;US5846987A;US2005288326A1;US7635704B2 | A61K31/47 | US20060097859 | KEARNEY BRIAN P;KAKEE ATSUYUKI;KAWAGUCHI ISAO | US2009233964A1 | GILEAD SCIENCES INC;JAPAN TOBACCO INC | ||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | C07D417/14;A61K31/427;A61P31/12;C07D277/24;C07D277/28;C07D295/13;C07D295/15 | Disclosed is a pharmaceutical composition comprising cobicistat / GS-9350 (as represented by formula IIBa) or a pharmaceutically acceptable salt thereof, in combination with two or three additional therapeutic agents selected from the group consisting of tenofovir disoproxil fumarate, emtricitabine, elvitegravir, efavirenz, atazanavir, darunavir, raltegravir, rilpivirine, and tenofovir alafenamide fumarate (GS-7340) wherein the compound of formula IIBa or pharmaceutically acceptable salt thereof is not in combination with tenofovir disoproxil fumarate, emtricitabine and elvitegravir, for treating an HIV infection or HCV infection in a human patient. Also disclosed is the use of cobicistat / GS-9350 (as represented by formula IIBa) or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for improving the pharmacokinetics of two or three additional therapeutic agents which are metabolized by cytochrome P450 monooxygenase or increasing the blood plasma level of the added therapeutic agents which are metabolized by cytochrome P450 monooxygenase, wherein the medicament is formulated for simultaneous, sequential or separate administration with a combination of said two or three additional therapeutic agents selected from the group consisting of tenofovir disoproxil fumarate, emtricitabine, elvitegravir, efavirenz, atazanavir, darunavir, raltegravir, rilpivirine, and GS-7340 wherein the combination of two or three additional therapeutic agents is not tenofovir disoproxil fumarate, emtricitabine and elvitegravir. | 20080222 | NZ(新西兰) | 20150828 | C07D417/14 | NZ20080612093 | LIU HONGTAO;DESAI MANOJ C;HONG ALLEN Y;VIVIAN RADALL W;XU LIANHONG;HUI HON C | NZ612093A | GILEAD SCIENCES INC | |||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | A61K31/426;A61K31/47;A61P31/18 | The invention provides methods for improving the pharmacokinetics of an HIV integrase inhibiting compound by administering food and/or ritonavir or a pharmaceutically acceptable salt thereof with the HIV integrase inhibitor. | 20061229 | EP(欧洲专利局) | 20110413 | WO2004067531A1;WO2004101512A2;EP1564210A1;WO2005112930A1;WO2005113508A1;WO9414436A1;US5567823A;US5541206A;US5635523A;US5648497A;US5674882A;US5846987A;US5886036A;US6037157A;US6703403B2;US49283303A;US2005239819A1;US2004167124A1;US34630506A;US2005288326A1 | A61K31/426 | EP20100193364 | KEARNEY BRIAN P;KAKEE ATSUYUKI;KAWAGUCHI ISAO | EP2308490A1 | GILEAD SCIENCES INC;JAPAN TOBACCO INC | ||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | A61K31/426;A61K31/47;A61P31/18 | The invention provides methods for improving the pharmacokinetics of an HIV integrase inhibiting compound by administering food and/or ritonavir or a pharmaceutically acceptable salt thereof with the HIV integrase inhibitor. | 20061229 | EP(欧洲专利局) | 20081008 | A61K31/426 | EP20060848393 | KEARNEY BRIAN P;KAKEE ATSUYUKI;KAWAGUCHI ISAO | EP1976517A1 | GILEAD SCIENCES INC;JAPAN TOBACCO INC | |||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | A61K31/5377;A61K9/20;A61K9/24;A61K31/4418 | Formulations of the HIV compounds atazanavir and cobicistat, and methods of treatment utilizing these formulations, are set forth. | 20141006 | US(美国) | 20160211 | US8461129B2;US6579851B2;US2013041004A1;US2013084243A1;US2013096073A1;US2011028412A1;US5558071A;WO2011127244A2 | A61K31/5377 | US201414425443 | KOO OTILIA MAY YUE;NIKFAR FARANAK;TAO JING;KOTTALA NIRANJAN KUMAR;VARIA SAILESH A | US2016038502A1 | SQUIBB BRISTOL MYERS CO | ||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | A61K31/513;A61K9/14;A61K9/20;A61K9/48;A61K31/427;A61K47/02;A61P31/18 | The invention relates to the field of the chemical and pharmaceutical industry. The present pharmaceutical composition exhibiting activity against HIV infection comprises lopinavir and ritonavir in an effective amount, and an aluminometasilicate. A solid, finished dosage form can be in the form of powders, tablets, combination tablets, capsules, dragees, or granules, covered with a shell, a suppository, or powders for producing suspensions. The dosage forms can be made according to a traditional method. The invention makes it possible to broaden the range of pharmaceutical compositions exhibiting antiviral activity and to improve their pharmacokinetic properties. | 20180615 | WO(世界知识产权局) | 20190103 | A61K31/513 | WO2018RU00396 | KHAZANOVA ELENA SERGEEVNA;NOGAI SERGEI UREVICH;YAKOVLEV DMITRY VLADIMIROVICH | WO2019004871A1 | LLC IZVARINO PHARMA | |||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | A61K31/513;A61K9/20;A61K31/427;A61K47/32;A61K47/34;A61P31/18 | The invention relates to the field of the pharmaceutical chemical industry. The present pharmaceutical composition for treating HIV infection comprises lopinavir and ritonavir in an effective amount, and a polymer. The pharmaceutical composition is produced by extrusion. The composition comprises, as the polymer, a matrix polymer consisting of PEG 6000 / vinylcaprolactam / vinyl acetate, at 5 to 25 % of the mass of the pharmaceutical composition, in combination with copovidone, at 45 to 65 % of the mass of the pharmaceutical composition. This invention makes it possible to broaden the range of available drugs with improved pharmacokinetic properties. | 20170825 | WO(世界知识产权局) | 20180329 | EA011924B1;US2016193151A1;US2013190337A1 | A61K31/513 | WO2017RU00622 | KHAZANOVA ELENA SERGEEVNA;NOGAI SERGEI UREVICH;IAKOVLEV DMITRII VLADIMIROVICH | WO2018056865A1 | LLC IZVARINO PHARMA | ||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | A61K31/00 | The present invention relates to stable amorphous form of a HIV protease inhibitor, namely, Atazanavir. The present invention preferably relates to stable amorphous form of Atazanavir free base. The present invention also relates to an improved process for the preparation of Atazanavir sulfate from amorphous Atazanavir free base. The present invention also relates to solid dispersion/premix comprising amorphous Atazanavir free base and a pharmaceutically acceptable excipient. | 20160909 | WO(世界知识产权局) | 20170316 | US8461347B2;WO2014125270A1 | A61K31/00 | WO2016IB55393 | VETUKURI PRASADA RAJU VNKV;GILLA GOVERDHAN;VEDANTHAM RAVINDRA;KAMMA YUVASAI KRISHNA;CHIGURUPATI KRISHNA PRASAD | WO2017042735A1 | GRANULES INDIA LTD;VETUKURI PRASADA RAJU VNKV;GILLA GOVERDHAN;VEDANTHAM RAVINDRA;KAMMA YUVASAI KRISHNA;CHIGURUPATI KRISHNA PRASAD | ||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | C07D491/147;A61K31/513;A61K31/519;A61P31/12;A61P31/14;C07D239/10;C07H19/073 | The invention relates to the field of organic chemistry and medicine, and more particularly to synthetic substances of the pyrimidine series, namely 2-chloro-5-phenyl-5H-pyrimido[5',4':5,6]pyrano[2,3-d]pyrimidine-4-ol derivatives, having antiviral activity. Claimed are a drug with antiviral activity against HIV infection and hepatitis B virus, containing 2-chloro-5-phenyl-5H-pyrimido[5',4':5,6]pyrano[2,3-d]pyrimidine-4-ol derivatives of the general formula shown, where: X is selected from the group: Н, NO2, Hal, ОМе R1 is selected from the group: Сl, ОН and R2 is selected from the group: Cl, SH, ОН and a drug with antiviral activity against HIV infection, containing a 2-chloro-5-phenyl-5H-pyrimido[5',4':5,6]pyrano[2,3-d]pyrimidine-4-ol derivative of the general formula shown, where: X is selected from the group: Н, NO2, Hal, ОМе R1 is selected from the group: Cl, ОН and R2 is selected from the group: Cl, SH, ОН in combination with a reverse transcriptase inhibitor selected from Retrovir, or in combination with a protease inhibitor selected from Lopinavir, in an effective amount. The result is an effective drug with antiviral activity. | 20160406 | WO(世界知识产权局) | 20161006 | RU2188201C2;RU2246496C1;US4578380A | C07D491/147 | WO2016RU00197 | TETS VIKTOR VENIAMINOVICH;TETS GEORGY VIKTOROVICH;KRASNOV KONSTANTIN ANDREEVICH | WO2016159836A1 | TETS VIKTOR VENIAMINOVICH;TETS GEORGY VIKTOROVICH | ||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | A61K31/381;A61K31/4402;A61P31/18 | The present invention provides a method of treating HIV-1 infection in a subject. The method comprises administering to the subject a combination of anti-HIV-1 agents wherein the combination comprises an effective dose of Apricitabine and an effective dose of Atazanavir. | 20121115 | WO(世界知识产权局) | 20130523 | US2009162319A1;WO2005082362A1 | A61K31/381 | WO2012AU01409 | COATES JONATHAN ALAN VICTOR;COX SUSAN WENDY | WO2013071353A1 | AVEXA LTD;COATES JONATHAN ALAN VICTOR;COX SUSAN WENDY | ||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | A61K31/34;A61K31/426;A61K31/4418;A61K31/505;A61K31/513;A61K31/52;A61K31/536;A61K31/661;A61K31/675;A61K31/7068;A61P31/18 | The invention relates to a pharmaceutical composition for treating the human immunodeficiency virus (HIV) in humans, including three or four active principles selected as: a nucleoside reverse transcriptase inhibitor (NARTI) selected from lamivudine and emtricitabine a nucleoside or nucleotide reverse transcriptase inhibitor (NARTI) selected from didanosine, abacavir and tenofovir and the combination of ritonavir with a protease inhibitor (PI) selected from lopinavir, fosamprenavir, atazanavir and darunavir or an non-nucleoside reverse transcriptase inhibitor (NNRTI) selected from efavirenz and etravirine for daily administration to said human being one to four days per week. | 20101119 | WO(世界知识产权局) | 20110526 | A61K31/34 | WO2010EP67851 | LEIBOWITCH JACQUES | WO2011061302A1 | ASSIST PUBL HOPITAUX DE PARIS;LEIBOWITCH JACQUES | |||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | C07D213/42;A61K31/435;A61P31/18 | The present invention relates to polymorphic Forms B and P of atazanavir sulfate and methods for their preparation. The present invention is also directed towards pharmaceutical compositions comprising the novel polymorphs of atazanavir sulfate and methods of treating HIV infection by administering to a patient in need thereof a therapeutically effective amount of the polymorphic Forms B and P of atazanavir sulfate. The present invention also describes process for preparation of amorphous atazanavir sulfate. | 20100902 | WO(世界知识产权局) | 20110310 | US2005256202A1;US6087383A;US5849911A;WO2010079497A2 | C07D213/42 | WO2010IB53964 | GANGULY SOMENATH;SANTHAKUMAR RITA;CHANDRASHEKHAR T G | WO2011027324A1 | RANBAXY LAB LTD;GANGULY SOMENATH;SANTHAKUMAR RITA;CHANDRASHEKHAR T G | ||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | C07F9/655;A61K31/655;A61P31/18 | The present invention relates to a crystalline form of fosamprenavir calcium. The crystalline form of the present invention is designated as Form II of fosamprenavir calcium. The present invention also relates to a process for the preparation of crystalline Form II of fosamprenavir calcium. The present invention further relates to a pharmaceutical composition comprising crystalline Form II of fosamprenavir calcium. The present invention relates further to a method of treating a HIV infection using crystalline Form II of fosamprenariv calium. | 20100629 | WO(世界知识产权局) | 20110106 | WO0004033A1;US6514953B1 | C07F9/655 | WO2010IB52974 | BHOGE SATISH MANOHAR;KSHIRSAGAR PRAKASH;RICHHARIYA SANTOSH;SINGH KAPTAN | WO2011001383A1 | RANBAXY LAB LTD;BHOGE SATISH MANOHAR;KSHIRSAGAR PRAKASH;RICHHARIYA SANTOSH;SINGH KAPTAN | ||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | C07F9/655;A61K31/665;A61P31/18 | The present invention relates to amorphous Fosamprenavir calcium and processes for its preparation, a pharmaceutical composition comprising it and a method for treating a HIV infection therewith. | 20100520 | WO(世界知识产权局) | 20101125 | WO0004033A1 | C07F9/655 | WO2010IB52251 | BHOGE SATISH MANOHAR;KSHIRSAGAR PRAKASH;RICHHARIYA SANTOSH;AGRAWAL ANSHUL;SINGH KAPTAN | WO2010134045A1 | RANBAXY LAB LTD;BHOGE SATISH MANOHAR;KSHIRSAGAR PRAKASH;RICHHARIYA SANTOSH;AGRAWAL ANSHUL;SINGH KAPTAN | ||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | A61K31/4965 | Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics of drugs that undergo in vivo degradation by cytochrome P450 enzymes. Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Specifically, methods of inhibiting metabolic degradation of atazanavir sulphate for administering to a patient suffering from HIV infection are disclosed. | 20090916 | WO(世界知识产权局) | 20100325 | US2008113945A1;US2006084628A1 | A61K31/4965 | WO2009US57183 | LUDTKE DOUGLAS;DAGGER RAYMOND | WO2010033614A1 | SEQUOIA PHARMACEUTICALS;LUDTKE DOUGLAS;DAGGER RAYMOND | ||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | A61K31/47;A61K31/472;A61K31/496;A61K31/506;A61K31/52;A61K31/536;A61K31/7072 | The present invention relates to a combination therapy for treating an HIV infection or inhibiting integrase comprising (S)-6-(3-chloro-2-fluorobenzyl)-1-(1-hydroxymethyl-2-methylpropyl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid ("Compound A") or a pharmaceutically acceptable solvate or salt thereof in combination with at least one other anti-HIV agent. In some embodiments of the present invention, the other anti-HIV agents are chosen from reverse transcriptase inhibitors and protease inhibitors. In certain embodiments of the present invention, the other anti-HIV agents are chosen from AZT, 3TC, PMPA, efavirenz, indinavir, nelfinavir, a combination of AZT/3TC, and a combination of PMPA/3TC. Since Compound A has a high inhibitory activity specific for integrases, when used in combinations with other anti-HIV agents it can provide a combination therapy with fewer side effects for humans. | 20050520 | WO(世界知识产权局) | 20051201 | EP1564210A1;WO0198275A2;WO0040563A1;US5985894A | A61K31/47 | WO2005JP09719 | MATSUZAKI YUJI;WATANABE WATARU;IKEDA SATORU;KANO MITSUKI | WO2005112930A1 | JAPAN TOBACCO INC;MATSUZAKI YUJI;WATANABE WATARU;IKEDA SATORU;KANO MITSUKI | ||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | A61K31/505;A61K31/513;A61K31/52;A61K31/65;A61K31/675;A61K31/70;A61K45/06 | The present invention relates to the use of a dioxolane thymine compound according to the chemical structure of Formula (I): where R<1> is H, an acyl group, a C1-C20 alkyl or ether group, a phosphate, diphosphate, triphosphate or phosphodiester group, for use in the treatment of HIV infections which exhibit resistance to 3TC and/or AZT. Preferably, compounds according to the present invention are combined with at least one anti-HIV agent which inhibits HIV by a mechanism other than through the inhibition of thymidine kinase (TK). These agents include those selected from among nucleoside reverse transcriptase inhibitors (NRTI), non-nucloeoside reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors, among others. These agents are generally selected from the group consisting of 3TC (Lamivudine), AZT (Zidovudine), (-)-FTC, ddI (Didanosine), ddC (zalcitabine), abacavir (ABC), tenofovir (PMPA), D-D4FC (Reverset), D4T (Stavudine), Racivir, L-D4FC, NVP (Nevirapine), DLV (Delavirdine), EFV (Efavirenz), SQVM (Saquinavir mesylate), RTV (Ritonavir), IDV (Indinavir), SQV (Saquinavir), NFV (Nelfinavir), APV (Amprenavir), LPV (Lopinavir), fuseon and mixtures thereof. The TK dependent agents, such as AZT and D4T, may be used in combination with one of the dioloxane thymine compounds according to the present invention, but the use of such agents may be less preferred. In preferred compositions according to the present invention, R is preferably H or a C2-C18 acyl group or a monophosphate group. Pharmaceutical compositions and methods of reducing the likelihood that a patient at risk for contract an HIV infection will contract the infection are other aspects of the present invention. | 20031208 | WO(世界知识产权局) | 20040624 | A61K31/505 | WO2003US39029 | CHU CHUNG K;SCHINAZI RAYMOND F | WO2004052296A2 | UNIV GEORGIA RES FOUND;UNIV EMORY;CHU CHUNG K;SCHINAZI RAYMOND F | |||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | A61K31/00;A61K31/16;A61K31/4412;A61K38/14;A61K38/55;A61K45/06;A61P35/00;A61P39/04 | The invention discloses pharmaceutical compositions for the treatment of viral infections, in particular the human immunodeficiency virus (HIV). The compositions comprises a iron chelator and an antiviral agent. Suitable iron chelators are selected from the group of hydroxymates (such as deferoxamine), from hydroxypyridones (such as deferipone) or from nucleic acid binding chemotherapeutics (such as bleomycin). Suitable antiviral agents are protease inhibitors, preferably ritonavir, or reverse transcriptase inhibitors, preferably dideoxyinosine. The invention describes a pharmaceutical product for the treatment of viral infections, in particular of the human immunodeficiency virus (HIV). According to the invention, the pharmaceutical product comprises a compound that as active component contains an iron chelator. Suitable iron chelators are selected from the group of hydroxamates (such as deferoxamine), the family of the hydroxypyridinons (such as deferiprone), and the nucleic acid-binding chemotherapeutical products (such as bleomycine). A synergistic effect is obtained in vitro when in addition to the component containing the iron chelator, a product is used that contains another virus-inhibiting compound. As the antiviral agent a protease-inhibitor, preferably ritonavir, is considered. Another suitable antiviral agent is a reverse transcriptase inhibitor, preferably a dideoxyinosine. | 20000809 | WO(世界知识产权局) | 20010222 | A61K31/00 | WO2000NL00559 | VAN ASBECK BERNT SWEDER;MARX JOHANNES JOSEPHUS MARIA | WO0112168A2 | FACULTEIT GENEESKUNDE UNIVERSI;ASBECK BERNT SWEDER VAN;MARX JOHANNES JOSEPHUS MARIA | |||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | A61K31/426;A61K31/41 | The invention relates to ritonavir bis-hydrochloride, processes for the preparation of the ritonavir bis-hydrochloride, pharmaceutical compositions containing the ritonavir bis-hydrochloride and made from it, and methods of using the ritonavir bis-hydrochloride to inhibit HIV protease or enhance the pharmacokinetics of compounds which are metabolized by cytochrome P450 3A4. | 20111216 | US(美国) | 20131203 | US5674882A;US6232333B1;US6407252B1 | A61K31/426 | US201113328043 | ACQUASALIENTE MAURIZIO;HOULLEMARE DIDIER;ZHANG GEOFF;SINGAM PULLA;MORRIS JOHN;MARSH KENNAN;BABCOCK MARTIN;PAVLINA JOHN;SHI YI;GONG YUCHUAN | US8598216B1 | ACQUASALIENTE MAURIZIO;HOULLEMARE DIDIER;ZHANG GEOFF;SINGAM PULLA;MORRIS JOHN;MARSH KENNAN;BABCOCK MARTIN;PAVLINA JOHN;SHI YI;GONG YUCHUAN;ABBVIE INC | ||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | C07C69/017;C07D209/48;C07D217/26;C07D263/14;C07D317/24;C07D327/10;C07D413/04;C07D413/06 | HIV protease inhibitors inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds can be prepared by the novel methods of the present invention using the novel inventive compounds and intermediates. | 19990428 | US(美国) | 20011016 | US5063208A;US5142056A;US5157041A;US5196438A;US5204471A;US5235039A;US5256783A;US5434265A;US5463104A;US5475136A;US5484926A;US5491166A;US5502061A;US5508407A;US5514802A;US5527829A;US5554653A;US5705647A;US5846993A;US5905077A;US5925759A;US5962725A;US6084107A;AU717637A;CA2075666A1;EP0337714A2;EP0346847A2;EP0356223A2;EP0361341A2;EP0402646A1;EP0432695A2;EP0432694A2;EP0434365A2;EP0490667A2;EP0498680A1;EP0526009A1;EP0533000A1;EP0539192A1;EP0560268A1;EP0579223A1;WO9108221A1;WO9304043A1;WO9313066A1;WO9323379A1;WO9404492A1;WO9405639A1;WO9509843A1;WO9628423A1;WO9711937A1;WO9711938A1;WO9730993A1 | C07C69/017 | US19990300835 | DEASON MICHAEL E;WHITTEN KATHLEEN R | US6303786B1 | AGOURON PHARMA;JAPAN TOBACCO INC | ||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | A61K31/675;A61K31/427;A61K31/4418;A61K31/513;A61K31/536;A61K31/635 | The present invention relates to a pharmaceutical composition for treating the human immunodeficiency virus (HIV) in humans, including three or four active principles selected as: a nucleoside reverse transcriptase inhibitor (NRTI) selected from lamivudine and emtricitabine a nucleoside or nucleotide reverse transcriptase inhibitor (NRTI) selected from didanosine, abacavir and tenofovir and the combination of a boosted or unboosted protease inhibitor (PI) selected from lopinavir, fosamprenavir, atazanavir and darunavir or an non-nucleoside reverse transcriptase inhibitor (NNRTI) selected from efavirenz and etravirine or an integrase inhibitor for daily administration to said human being one to four days per week. | 20150623 | US(美国) | 20151231 | US2012270828A1;US2012283177A1 | A61K31/675 | US201514747621 | LEIBOWITCH JACQUES | US2015374727A1 | UNIVERSIT?? VERSAILLES SAINT QUENTIN EN YVELINES | ||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | C07D493/04;A61K9/20 | The present invention provides new pseudopolymorphic forms of darunavir as well as a novel amorphous form of darunavir, pharmaceutical compositions comprising these compounds, methods for their preparation and use thereof in treating retroviral infections, in particular, HIV infection. | 20141124 | US(美国) | 20150528 | US8921415B2 | C07D493/04 | US201414551497 | MAROM EHUD | US2015148412A1 | MAPI PHARMA LTD | ||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | A61K31/7072;A61K31/39;A61K31/47;A61K31/472;A61K31/496;A61K31/506;A61K31/52;A61K31/536;A61K31/675 | The present invention relates to a combination therapy for treating an HIV infection or inhibiting integrase comprising (S)-6-(3-Chloro-2-fluorobenzyl)-1-(1-hydroxymethyl-2-methylpropyl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (??Compound A??) or a pharmaceutically acceptable solvate or salt thereof in combination with at least one other anti-HIV agent. In some embodiments of the present invention, the other anti-HIV agents are chosen from reverse transcriptase inhibitors and protease inhibitors. In certain embodiments of the present invention, the other anti-HIV agents are chosen from AZT, 3TC, PMPA, efavirenz, indinavir, nelfinavir, a combination of AZT/3TC, and a combination of PMPA/3TC. Since Compound A has a high inhibitory activity specific for integrases, when used in combinations with other anti-HIV agents it can provide a combination therapy with fewer side effects for humans. | 20131212 | US(美国) | 20141211 | A61K31/7072 | US201314104398 | MATSUZAKI YUJI;WATANABE WATARU;IKEDA SATORU;KANO MITSUKI | US2014364389A1 | JAPAN TOBACCO INC | |||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | A61K31/4418;A61K45/06;B29B9/12 | Disclosed are compressed tablets containing atazanavir sulfate and an acidifying agent, optionally with another active agent, e.g., anti-HIV agents, and optionally with precipitation retardant agents. Also disclosed are processes for making the tablets, and methods of treating HIV. | 20110407 | US(美国) | 20130808 | A61K31/4418 | US201113639544 | NIKFAR FARANAK;HUSSAIN MUNIR ALWAN;QIAN FENG | US2013203759A1 | NIKFAR FARANAK;HUSSAIN MUNIR ALWAN;QIAN FENG | |||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | A61K31/34;A61K31/427;A61P31/14;A61P31/18;C07D493/04 | The present invention provides new pseudopolymorphic forms of darunavir as well as a novel amorphous form of darunavir, pharmaceutical compositions comprising these compounds, methods for their preparation and use thereof in treating retroviral infections, in particular, HIV infection. | 20120725 | US(美国) | 20130124 | A61K31/34 | US201213557991 | MAROM EHUD | US2013023570A1 | MAPI PHARMA LTD;MAROM EHUD | |||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | A61K31/635;A61P31/14;A61P31/18;C07D493/04 | The present invention provides new pseudopolymorphic forms of darunavir as well as a novel amorphous form of darunavir, pharmaceutical compositions comprising these compounds, methods for their preparation and use thereof in treating retroviral infections, in particular, HIV infection. | 20091208 | US(美国) | 20120209 | A61K31/635 | US200913146727 | MAROM EHUD | US2012035142A1 | MAROM EHUD;MAPI PHARMA LTD | |||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | A61K31/635;A61K31/4418;A61K31/4433;A61K31/4725;A61P31/18;C07D213/42;C07D401/12;C07D405/12;C07D493/04 | Provided herein (among other things) are protease inhibitor compounds having enhanced features, along with methods for administering such compounds. For example, the subject compounds can be administered without concomitant administration of a CYP3A4 inhibitor, have increased therapeutic index and/or increased potency, and are low-resistance inducing in nature. Exemplary potent HIV protease inhibitors are mono-m-PEG3-atazanavir, mPEGn-N-darunavir (wherein n is 3 or 5), mPEGn-NHCO-saquinavir (wherein n is 5 or 7), and di-mPEG3-atazanavir. | 20090917 | US(美国) | 20110811 | US8598364B2;US2005136031A1;US5672662A;US2004224900A1 | A61K31/635 | US200913119079 | JUDE-FISHBURN C SIMONE;VANDER VEEN LAURIE A;RILEY TIMOTHY A | US2011195940A1 | NEKTAR THERAPEUTICS | ||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | A61K31/4418;A61K31/16;A61P31/12;C07C231/02;C07C243/26;C07D213/42 | A process is provided for preparing the HIV protease inhibitor atazanavir bisulfate wherein a solution of atazanavir free base is reacted with concentrated sulfuric acid in an amount to react with less than about 15% by weight of the free base, seeds of Form A crystals of atazanavir bisulfate are added to the reaction mixture, and as crystals of the bisulfate form, additional concentrated sulfuric acid is added in multiple stages at increasing rates according to a cubic equation, to effect formation of Form A crystals of atazanavir bisulfate. A process is also provided for preparing atazanavir bisulfate as Pattern C material. A novel form of atazanavir bisulfate is also provided which is Form E3 which is a highly crystalline triethanolate solvate of the bisulfate salt from ethanol. | 20101008 | US(美国) | 20110526 | US7838678B2;US4800084A;US5489436A;US2004022855A1;US4022776A;US5428048A;US4847265A;US5541205A;US6086919A;US6087383A;US2002094992A1;US658435A;US3980637A;US2005214373A1;US5158777A;US6136345A;US6316438B1;US2005256314A1;US5849911A;US2005266080A1;US2005288343A1 | A61K31/4418 | US20100900588 | KIM SOOJIN;LOTZ BRUCE T;MALLEY MARY F;GOUGOUTAS JACK Z;DAVIDOVICH MARTHA;SRIVASTAVA SUSHIL K | US2011124689A1 | SQUIBB BRISTOL MYERS CO | ||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | A61K31/551;A61K31/522 | The invention relates to an anti-HIV combination comprising (i) tenofovir or its disoproxil fumarate derivative (ii) ritonavir and (iii) TMC 114, useful for the treatment or prevention of HIV infections. It further relates to pharmaceutical formulations containing such combinations. | 20050708 | US(美国) | 20070906 | A61K31/551 | US20050571599 | HOETELMANS RICHARD MARINUS W | US2007208009A1 | HOETELMANS RICHARD MARINUS W | |||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | A61K31/47;C12N9/99;A61K39/00;A61P31/18;A61P43/00;C07D217/26;C07D239/10;C07D277/28;C07D307/20;C07D401/12;C07D401/14;C07D403/12;C07D405/12;C07D417/14;C07D495/04;C07K14/00;C07K14/765;C07K14/795;C07K16/00;C07K16/38;C07K16/44;C12N5/10;C12P21/08 | Activated haptens useful for generating immunogens to HIV protease inhibitors, immunogens useful for producing antibodies to HIV protease inhibitors, and antibodies and labeled conjugates useful in immunoassays for the HIV protease inhibitor saquinavir. The novel haptens feature an activated functionality at the central, non-terminal hydroxyl group. Also described are monoclonal antibodies specific for saquinavir having less than 10% cross-reactivity with lopinavir, nelfinavir, amprenavir, ritonavir, and indinavir, and a murine hybridoma producing said antibodies. | 20070126 | US(美国) | 20070628 | US2003010088A1 | A61K31/47 | US20070627572 | SIGLER GERALD F;HUI RAYMOND A;DERAS INA;ROOT RICHARD T;GHOSHAL MITALI;HUBER ERASMUS;VON DER ELTZ HERBERT W;METZ SIGRUN;KERN PETER | US2007149565A1 | SIGLER GERALD F;HUI RAYMOND A;DERAS INA;ROOT RICHARD T;GHOSHAL MITALI;HUBER ERASMUS;VON DER ELTZ HERBERT W;METZ SIGRUN;KERN PETER | ||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | C07D403/02;C07K16/38;C07K16/44 | Activated haptens useful for generating immunogens to the HIV protease inhibitor atazanavir, immunogens useful for producing antibodies to atazanavir, and antibodies and labeled conjugates useful in immunoassays for determination of atazanavir. The haptens feature an activated functionality at the central, non-terminal hydroxyl group. | 20061222 | US(美国) | 20070621 | US6087383A;US6635745B2 | C07D403/02 | US20060615092 | ROOT RICHARD T;HUI RAYMOND A | US2007142641A1 | ROCHE DIAGNOSTICS OPERATIONS | ||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | A61K31/47;A61K31/472;A61K31/496;A61K31/506;A61K31/52;A61K31/536;A61K31/7072 | The present invention relates to a combination therapy for treating an HIV infection or inhibiting integrase comprising (S)-6-(3-Chloro-2-fluorobenzyl)-1-(1-hydroxymethyl-2-methylpropyl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid ("Compound A") or a pharmaceutically acceptable solvate or salt thereof in combination with at least one other anti-HIV agent. In some embodiments of the present invention, the other anti-HIV agents are chosen from reverse transcriptase inhibitors and protease inhibitors. In certain embodiments of the present invention, the other anti-HIV agents are chosen from AZT, 3TC, PMPA, efavirenz, indinavir, nelfinavir, a combination of AZT/3TC, and a combination of PMPA/3TC. Since Compound A has a high inhibitory activity specific for integrases, when used in combinations with other anti-HIV agents it can provide a combination therapy with fewer side effects for humans. | 20050520 | US(美国) | 20051229 | US7176220B2;US2005054645A1;US6248736B1;US6248739B1;US2004127708A1;US2002103220A1;US3472859A;US2005239819A1;US5985894A | A61K31/47 | US20050133463 | MATSUZAKI YUJI;WATANABE WATARU;IKEDA SATORU;KANO MITSUKI | US2005288326A1 | MATSUZAKI YUJI;WATANABE WATARU;IKEDA SATORU;KANO MITSUKI | ||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | A61K31/16;C07C231/02;C07C243/26;C07D213/42 | A process is provided for preparing the HIV protease inhibitor atazanavir bisulfate wherein a solution of atazanavir free base is reacted with concentrated sulfuric acid in an amount to react with less than about 15% by weight of the free base, seeds of Form A crystals of atazanavir bisulfate are added to the reaction mixture, and as crystals of the bisulfate form, additional concentrated sulfuric acid is added in multiple stages at increasing rates according to a cubic equation, to effect formation of Form A crystals of atazanavir bisulfate. A process is also provided for preparing atazanavir bisulfate as Pattern C material. A novel form of atazanavir bisulfate is also provided which is Form E3 which is a highly crystalline triethanolate solvate of the bisulfate salt from ethanol. | 20050502 | US(美国) | 20051117 | US4800084A;US5489436A;US6727271B2;US6395767B2;US5428048A;US6753012B2;US4847265A;US5541205A;US6086919A;US6087383A;US2002094992A1;US6414002B1;US6429210B1;US2005214373A1;US5158777A;US6136345A;US6316438B1;US6653314B2;US2005256314A1;US5849911A;US6670344B2;US2005266080A1;US2005288343A1 | A61K31/16 | US20050119558 | KIM SOOJIN;LOTZ BRUCE T;MALLEY MARY F;GOUGOUTAS JACK Z;DAVIDOVICH MARTHA;SRIVASTAVA SUSHIL K | US2005256202A1 | KIM SOOJIN;LOTZ BRUCE T;MALLEY MARY F;GOUGOUTAS JACK Z;DAVIDOVICH MARTHA;SRIVASTAVA SUSHIL K | ||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | A61K31/505;A61K31/513;A61K31/52;A61K31/65;A61K31/675;A61K31/70;A61K45/06 | The present invention relates to the use of a dioxolane thymine compound according to the chemical structure of Formula (I): where R1 is H, an acyl group, a C1-C20 alkyl or ether group, a phosphate, diphosphate, triphosphate or phosphodiester group, for use in the treatment of HIV infections which exhibit resistance to 3TC and/or AZT. Preferably, compounds according to the present invention are combined with at least one anti-HIV agent which inhibits HIV by a mechanism other than through the inhibition of thymidine kinase (TK). These agents include those selected from among nucleoside reverse transcriptase inhibitors (NRTI), non-nucloeoside reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors, among others. These agents are generally selected from the group consisting of 3TC (Lamivudine), AZT (Zidovudine), (-)-FTC, ddI (Didanosine), ddC (zalcitabine), abacavir (ABC), tenofovir (PMPA), D-D4FC (Reverset), D4T (Stavudine), Racivir, L-D4FC, NVP (Nevirapine), DLV (Delavirdine), EFV (Efavirenz), SQVM (Saquinavir mesylate), RTV (Ritonavir), IDV (Indinavir), SQV (Saquinavir), NFV (Nelfinavir), APV (Amprenavir), LPV (Lopinavir), fuseon and mixtures thereof. The TK dependent agents, such as AZT and D4T, may be used in combination with one of the dioloxane thymine compounds according to the present invention, but the use of such agents may be less preferred. In preferred compositions according to the present invention, R1 is preferably H or a C2-C18 acyl group or a monophosphate group. Pharmaceutical compositions and methods of reducing the likelihood that a patient at risk for contract an HIV infection will contract the infection are other aspects of the present invention. | 20050401 | US(美国) | 20050922 | US5276151A;US6350753B1;US6855821B2;US5041449A;US7119202B1;US5852027A | A61K31/505 | US20050530088 | CHU CHUNG K;SCHINAZI RAYMOND F | US2005209196A1 | CHU CHUNG K;SCHINAZI RAYMOND F | ||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | A61K31/522;A61K31/551 | The present invention includes a group of novel compounds that are demonstrated to potently and selectively inhibit HIV integrase (IN) activity in vitro and to potently inhibit HIV replication in live, cultured cells at non-toxic concentrations. The novel compounds disclosed include 2,3-di(3,4-dihydroxy-dihydroxydihydrocinnamoyl)-L-tartaric acid, 2,3-di-(3,4-dihydroxybenzoyl)-L-tartaric acid, 2,3-di-(3,4-dihydroxyphenylacetyl)-L-tartaric acid, 2,3-di-(3,4,5-trihydroxybenzoyl-L-tartaric acid, 2,3-dicaffeoyldiamidopropionic acid, 1,2,-dicaffeoyl-L-glyceric acid, bis,-3,4-dicaffeoyldiamidobenzoic acid, di-3,4-dihydroxybenzylidene succinic acid, di-3,4-dihydrodihydroxybenzylidine succinic acid, 2,3-dicaffeoyl-L-serine, bis-dicaffeoyl-L-isoserine and 1,4-dicaffeoyl-L-lysine. Tests of integrase inhibitors with 2',3'-dideoxycytidine, zidovudine and nelfinavir (protease inhibitor) indicated a potent synergy against reverse transcriptase inhibitor resistant virus. The potential benefit from the addition of integrase inhibitors to combination drug therapies is significant. | 20030925 | US(美国) | 20050303 | US5705647A;US4724232A;US5759842A;US5663161A | A61K31/522 | US20030672724 | ROBINSON W EDWARD;KING PETER J;REINECKE MANFRED G | US2005049242A1 | |||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | A61K31/426;A61K9/14;A61K9/16;A61K9/20;A61K31/4425;A61K31/4433;A61K31/472;A61K31/4725;A61K31/496;A61K31/505;A61K47/00;A61K47/02;A61P31/18 | FIELD: pharmaceutics.SUBSTANCE: invention relates to the chemical and pharmaceutical industry, and more particularly to a pharmaceutical composition for preventing and treating HIV infection. Pharmaceutical composition contains a HIV protease inhibitor representing ritonavir and magnesium aluminometasilicate in a weight ratio of 1:(0.5?C1.5). Magnesium aluminometasilicate is Neusilin. Ritonavir includes polymorphic form 1, polymorphic form 2, or combinations thereof. Pharmaceutical composition is prepared in solid form.EFFECT: composition, according to the invention, using magnesium aluminometasilicate Neusilinprovides close solubility characteristics, regardless of the polymorphic form of ritonavir used.9 cl, 1 tbl, 2 ex | 20170320 | RU(俄罗斯联邦) | 20180806 | A61K31/426 | RU20170109102 | ZOLOTOV SERGEJ ANATOLEVICH;LUBENETS NADEZHDA LEONIDOVNA;IGNATEV ALEKSEJ VLADIMIROVICH | RU2663466C1 | OBSHCHESTVO S OGRANICHENNOJ OTVETSTVENNOSTYU MBA GRUPP | |||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | A61K31/427;A61K9/08;A61K9/52;A61K31/34;A61K38/06;A61P31/12;A61P31/18;B82B1/00 | FIELD: medicine.SUBSTANCE: group of inventions refers to the long-term use of an parenteral formulation for producing a medicinal preparation for treating a HIV-infected individual with the above preparation applicable for subcutaneous or intramuscular injections and consists of brecanavir, or its salt in the form of an aqueous micro- or nanoparticle suspension containing Polysorbate 20, and is administered at regular intervals from 6 to 12 months, and to the above pharmaceutical composition.EFFECT: reducing the number of injections of the composition (preparation) in the absence of the additional agent ritonavir.7 cl, 4 dwg, 4 tbl | 20100922 | RU(俄罗斯联邦) | 20151120 | A61K31/427 | RU20120116070 | BART LIVEN EHLVIRE KOLETT;KRAUS GJUNTER | RU2569058C2 | TIBOTEK FARMAS JUTIKALZ | |||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | C07D493/04;A61K31/34;A61K31/365;A61K31/4164;A61K31/427;A61K31/496;A61K31/635;A61K45/00;A61P31/12;A61P31/18;A61P43/00 | Disclosed is a combination comprising a hexahydrofuro[2,3-b]furanyl containing HIV protease inhibitor of formula (4) and ritonavir. The combination is used in the manufacture of medicaments for the treatment of diseases associated with retrovirus infection in a mammal. | 20021212 | NZ(新西兰) | 20060428 | C07D493/04 | NZ20020533826 | VAN DER GEEST RONALD;STOFFELS PAUL;GROEN CORNELIS;JOCHMANS DIRK EDWARD DESIRE | NZ533826A | TIBOTEC PHARM LTD | |||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | C07D213/127;A61K31/16;A61K31/44;C07C231/02;C07C243/26;C07D213/42 | A process is provided for preparing the HIV protease inhibitor atazanavir bisulfate wherein a solution of atazanavir free base is reacted with concentrated sulfuric acid in an amount to react with less than about 15% by weight of the free base, seeds of Form A crystals of atazanavir bisulfate are added to the reaction mixture, and as crystals of the bisulfate form, additional concentrated sulfuric acid is added in multiple stages at increasing rates according to a cubic equation, to effect formation of Form A crystals of atazanavir bisulfate. A process is also provided for preparing atazanavir bisulfate as Pattern C material. A novel form of atazanavir bisulfate is also provided which is Form E3 which is a highly crystalline triethanolate solvate of the bisulfate salt from ethanol. ? KIPO & WIPO 2007 | 20050503 | KR(韩国) | 20070111 | C07D213/127 | KR20067025370 | KIM SOO JIN;LOTZ BRUCE T;MALLEY MARY F;GOUGOUTAS JACK Z;DAVIDOVICH MARTHA;SRIVASTAVA SUSHIL K | KR20070006935A | SQUIBB BRISTOL MYERS CO | |||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | A61K31/425;A61K9/48;A61K31/17;A61K31/341;A61K31/426;A61K31/4433;A61K31/45;A61K31/4545;A61K31/47;A61K31/4704;A61K31/4709;A61K31/472;A61K31/4725;A61K31/496;A61K31/513;A61K31/535;A61K31/5375;A61K31/55;A61K31/551;A61K31/635;A61K38/05;A61K38/55;A61K45/08;A61K47/10;A61K47/12;A61K47/26;A61K47/42;A61K47/44;A61P31/18;A61P43/00 | A liquid pharmaceutical composition providing improved oral bioavailability is disclosed for compounds which are inhibitors of HIV protease. In particular, the composition comprises a solution in a pharmaceutically acceptable organic solvent of (a) the HIV protease inhibitor and optionally, (b) a surfactant. The composition can optionally be encapsulated in either hard gelatin capsules or soft elastic capsules (SEC). | 19990520 | KR(韩国) | 20050323 | A61K31/425 | KR19997004469 | KR100478075B1 | |||||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | C07D249/14;A61K31/4196;A61K31/428;A61K31/4355;A61K31/4365;A61K31/4375;A61K31/4439;A61K31/454;A61K31/4545;A61K31/4709;A61K31/4725;A61K31/473;A61K31/496;A61K31/497;A61K31/498;A61K31/501;A61K31/502;A61K31/5025;A61K31/506;A61K31/517;A61K31/519;A61K31/5377;A61K31/63;A61P9/00;A61P13/12;A61P15/00;A61P17/06;A61P19/02;A61P19/10;A61P27/02;A61P27/12;A61P29/00;A61P35/00;A61P35/02;A61P43/00;C07D401/04;C07D403/04;C07D413/12;C07D417/04;C07D471/04;C07D491/048;C07D491/052;C07D495/04;C07D495/14 | PROBLEM TO BE SOLVED: To provide oral solid dosage forms for human immunodeficiency virus (HIV) protease inhibitors which have suitable oral bioavailability and stability and which do not necessitate high vehicle volumes.SOLUTION: An oral solid pharmaceutical dosage form includes a solid dispersion product of: an HIV protease inhibitor such as ritonavir and lopinavir a water-soluble polymer, such as a copolymer of N-vinyl pyrrolidone and vinyl acetate, having a Tg of at least about 50°C and a surfactant, such as sorbitan fatty acid ester.SELECTED DRAWING: None | 20151207 | JP(日本) | 20160526 | JP2006515313A;WO2006034116A1;WO2006050249A1 | C07D249/14 | JP20150238896 | DANE GOFF;ZHANG JING;SYLVAIN CATHERINE;SINGH RAJINDER;SACHA HOLLAND;YU JIAXIN;THILO HECKRODT;DING PINGYU | JP2016094437A | RIGEL PHARMACEUTICALS INC | ||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | A61K31/427;A61K9/24;A61K9/48;A61K31/34;A61P31/18;A61P43/00 | PROBLEM TO BE SOLVED: To provide a novel antiretroviral combination pharmaceutical composition.SOLUTION: A combination therapy pharmaceutical composition contains a solid dosage form containing ritonavir or a pharmaceutically acceptable salt thereof and ester, and darunavir or a pharmaceutically acceptable salt thereof and ester, wherein the dosage form is a tablet form, which comprises a first layer containing the ritonavir, and a second layer containing the darunavir. It is effective for treatment-naive and treatment experienced patients. It is non-toxic and is highly potent against wide variety of and multidrug-resistant HIV (human immunodeficiency virus) strains and further is readily to produce. | 20140806 | JP(日本) | 20150115 | JP2005511723A;WO2007068934A2;JP2007504142A | A61K31/427 | JP20140160671 | AMAR LULLA;GEENA MALHOTRA | JP2015007071A | CIPLA LTD | ||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | C07D277/28;A61K31/426;A61K31/427;A61P31/18;A61P37/04;C07D277/24;C07D277/30;C07D277/36;C07D277/40;C07D277/42;C07D417/12 | PROBLEM TO BE SOLVED: To provide a new crystalline polymorph of ritonavir, which is an inhibitor of human immunodeficiency virus (HIV) protease and HIV infection, and methods for its preparation.SOLUTION: The methods for preparing a new crystalline polymorph of ritonavir comprise crystallization by adding a poor solvent to ritonavir dissolved in a good solvent. The new crystalline polymorph of ritonavir has characteristic peaks in powder X-ray diffraction patterns at values of 2?? of 8.67???0.1??, 9.88???0.1??, 16.11???0.1??, 16.70???0.1??, 17.36???0.1??, 17.78???0.1??, 18.40???0.1??, 18.93???0.1??, 20.07???0.1??, 20.65???0.1??, 21.71???0.1?? and 25.38???0.1??. For the preparation, hexane is added to a solution of ritonavir Form I in methylene chloride or methanol. | 20131211 | JP(日本) | 20140424 | WO9639398A1;JPH08505844A | C07D277/28 | JP20130255680 | BAUER JOHN F;SALEKI-GERHARDT AZITA;NARAYANAN BIKSHANDARKOIL A;CHEMBURKAR SANJAY R;PATEL KETAN;SPIWEK HARRY O;BAUER PHILIP E;ALLEN KIMBERLY A | JP2014074047A | ABBVIE INC | ||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | A61K31/4439;A61K31/4709;A61K31/662;A61K31/7068;A61K31/7072;A61K31/708;A61P31/18 | Anti-HIV composition contains 2-carbamoyloxymethyl-5-(3,5-dichlorophenylthio)-4-isopropyl-1-(pyridin-4-yl)methyl-1H-imidazole (CDIMI) or its salt and at least one other anti-HIV agent. Preferably the additional anti-HIV agent is preferably AZT, ddI, ddC, 3TC, saquinavir and/or foscarnet. | 19970314 | HU(匈牙利) | 20000428 | A61K31/4439 | HU19990002175 | FUJIWARA TAMIO | HU9902175A2 | ||||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | A61K31/5025;A61K45/06;A61P31/18 | The present invention relates to pharmaceutical antiretroviral compositions comprising a combination of antiretroviral agents (darunavir, dolutegravir and ritonavir), the manufacturing process thereof and use of the said compositions for the prevention, treatment or prophylaxis of HIV infection. | 20170727 | EP(欧洲专利局) | 20190619 | A61K31/5025 | EP20170838879 | BANDI PARTHASARATHI REDDY;PODILE KHADGAPATHI;TIWARI SUNIL DEVIPRASAD;SHETIYA PRAKASH;MEDUM BALAKRISHNAIAH | EP3496718A1 | HETERO LABS LTD | |||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | C07C303/40;C07C311/41 | The present invention relates to an industrially feasible and economically viable process for the preparation of (1S,2R)-3-[4-aminophenyl)-sulfonylamino]-2-hydroxy-1-(phenyl-methyl)propyl] amine of formula I and its salt thereof and optionally converting it to HIV-protease inhibitors like Darunavir, Amprenavir or its prodrug Fosamprenavir. | 20150827 | EP(欧洲专利局) | 20160323 | WO2011048604A2;WO2005063770A1;WO2013108105A2;US5843946A;US6248775B1;US7772411B2;WO2013011485A1 | C07C303/40 | EP20150182635 | AGARWAL NAND LAL;HIRPARA HITIN MAGANBHAI;MISTRI PRANAV POPATLAL;PATEL NITIN MAGANBHAI | EP2998291A1 | ZCL CHEMICALS LTD | ||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | C07F9/655;A61K31/655;A61P31/18 | The present invention relates to a crystalline form of fosamprenavir calcium. The crystalline form of the present invention is designated as Form II of fosamprenavir calcium. The present invention also relates to a process for the preparation of crystalline Form II of fosamprenavir calcium. The present invention further relates to a pharmaceutical composition comprising crystalline Form II of fosamprenavir calcium. The present invention relates further to a method of treating a HIV infection using crystalline Form II of fosamprenariv calium. | 20100629 | EP(欧洲专利局) | 20120509 | C07F9/655 | EP20100740308 | BHOGE SATISH MANOHAR;KSHIRSAGAR PRAKASH;RICHHARIYA SANTOSH;SINGH KAPTAN | EP2448949A1 | RANBAXY LAB LTD | |||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | C07F9/655;A61K31/665;A61P31/18 | The present invention relates to amorphous Fosamprenavir calcium and processes for its preparation, a pharmaceutical composition comprising it and a method for treating a HIV infection therewith. | 20100520 | EP(欧洲专利局) | 20120328 | C07F9/655 | EP20100724900 | BHOGE SATISH MANOHAR;KSHIRSAGAR PRAKASH;RICHHARIYA SANTOSH;AGRAWAL ANSHUL;SINGH KAPTAN | EP2432788A1 | RANBAXY LAB LTD | |||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | A61K31/4965;A61K9/14 | Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics of drugs that undergo in vivo degradation by cytochrome P450 enzymes. Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Specifically, methods of inhibiting metabolic degradation of atazanavir sulphate for administering to a patient suffering from HIV infection are disclosed. | 20090916 | EP(欧洲专利局) | 20110629 | US2008113945A1;US2007218138A1 | A61K31/4965 | EP20090815132 | LUDTKE DOUGLAS;DAGGER RAYMOND | EP2337565A1 | SEQUOIA PHARMACEUTICALS | ||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | A61K31/337;C07D243/04;A61K31/335;A61K31/336;A61K31/34;A61K31/341;A61K31/395;A61K31/425;A61K31/426;A61K31/44;A61K31/4427;A61K31/445;A61K31/453;A61K31/47;A61K31/472;A61K31/498;A61K31/535;A61K31/5375;A61K31/55;A61K31/7048;A61K38/05;A61K38/06;A61K38/55;A61K45/06;A61P31/12;A61P31/18;C07D217/22;C07D277/24;C07D277/28;C07D295/08;C07D295/18;C07D303/46;C07D307/20;C07D401/14;C07D417/12;C08F2/34 | There is described a combination of ritonavir or a pharmaceutically acceptable salt thereof in combination with another HIV protease inhibitor, formulated as a single or separate composition, for use in the inhibition or treatment of an HIV infection or AIDS in a human host. | 19960628 | EP(欧洲专利局) | 20140108 | A61K31/337 | EP20100185624 | NORBECK DANIEL W;KEMPF DALES J;LEONARD JOHN M;BERTZ RICHARD J | EP2295052B1 | ABBVIE INC | |||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | A61K31/47;A61K31/472;A61K31/496;A61K31/506;A61K31/52;A61K31/536;A61K31/7072;A61P31/18;A61P43/00 | The present invention relates to a combination therapy for treating an HIV infection or inhibiting integrase comprising (S)-6-(3-chloro-2-fluorobenzyl)-1-(1-hydroxymethyl-2-methylpropyl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid ("Compound A") or a pharmaceutically acceptable solvate or salt thereof in combination with at least one other anti-HIV agent. In some embodiments of the present invention, the other anti-HIV agents are chosen from reverse transcriptase inhibitors and protease inhibitors. In certain embodiments of the present invention, the other anti-HIV agents are chosen from AZT, 3TC, PMPA, efavirenz, indinavir, nelfinavir, a combination of AZT/3TC, and a combination of PMPA/3TC. Since Compound A has a high inhibitory activity specific for integrases, when used in combinations with other anti-HIV agents it can provide a combination therapy with fewer side effects for humans. | 20050520 | EP(欧洲专利局) | 20100922 | EP1564210A1;WO0198275A2;WO0040563A1;US5985894A;WO02070486A1;WO0236734A2;WO02055079A2;US3472859A;JPS482672A;JP2002534416A;WO0040561A1;US6248739B1;EP1140850A1;JP2002534417A;US6248736B1;EP1140851A1;US2002103220A1;JPH04360872A;EP0498721B1 | A61K31/47 | EP20100161346 | MATSUZAKI YUJI;WATANABE WATARU;IKEDA SATORU;KANO MITSUKI | EP2229945A1 | JAPAN TOBACCO INC | ||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | C07D493/04 | The present invention relates to process for the preparation of Darunavir or a solvate thereof of Formula (I) using a novel intermediate (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl (2S,3R)-4-(4-(1,3-dioxoisoindolin-2-yl)-N-isobutylphenylsulfonamido)-3 -hydroxy- 1 -phenylbutan-2- ylcarbamate Compound of formula (II): The present invention also relates to the process for the preparation of novel intermediates (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl (2S,3R)-4-(4-(l,3-dioxo iso indolin-2-yl)-N-isobutylphenylsulfonamido)-3 -hydroxy-1-phenylbutan-2-ylcarbamate Compound of formula (II). Darunavir or its solvate of formula (I) are useful therapeutic agent and used in treatment of antiviral diseases. | 20170721 | WO(世界知识产权局) | 20180125 | C07D493/04 | WO2017IB54420 | CHIGURUPATI KRISHNA PRASAD;AREVELI SRINIVAS;GILLA GOVERDHAN;RAPOLU RAJESH KUMAR;VETUKURI PRASADA RAJU VNKV | WO2018015929A1 | GRANULES INDIA LTD | |||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | A61K31/513;A61K9/16;A61K9/20;A61K9/28;A61K31/426;A61K31/427 | The present invention provides a pharmaceutical dosage formulation, and more particularly, to a pharmaceutical dosage formulation comprising an HIV protease inhibitor. | 20060221 | EP(欧洲专利局) | 20110216 | A61K31/513 | EP20100184860 | ROSENBERG JOERG;REINHOLD ULRICH;LIEPOLD BERND;BERNDL GUNTHER;ALANI LAMAN;GHOSH SOUMOJEET;BREITENBACH JOERG | EP2283844A1 | ABBOTT LAB | |||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | A61K31/425;A61K9/48;A61K31/17;A61K31/426;A61K31/427;A61K31/4427;A61K31/4433;A61K31/4709;A61K31/472;A61K31/4725;A61K31/496;A61K31/513;A61K31/5375;A61K31/551;A61K31/63;A61K45/00;A61K47/10;A61K47/12;A61K47/30;A61K47/42;A61P31/00;A61P31/18;A61P43/00 | Improved pharmaceutical compositions are provided comprising one or more HIV protease inhibiting compounds having improved dissolution properties in a mixture of a fatty acid, ethanol, and water. | 20000525 | EP(欧洲专利局) | 20060705 | A61K31/425 | EP20000937743 | ALANI LAMAN A;GHOSH SOUMOJEET | EP1183026B1 | ABBOTT LAB | |||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | A61K31/425;A61K9/48;A61K31/17;A61K31/426;A61K31/427;A61K31/4433;A61K31/4709;A61K31/472;A61K31/4725;A61K31/496;A61K31/513;A61K31/5375;A61K31/551;A61K31/63;A61K45/00;A61K47/10;A61K47/12;A61K47/30;A61K47/42;A61P31/18;A61P43/00 | In the present invention, there is provided a pharmaceutical composition having improved dissolution comprising ritonavir or a combination of ritonavir and another HIV protease inhibiting compound, a pharmaceutically acceptable organic solvent comprising 40 to 75 percent by weight (based on the solution total weight) of a long chain fatty acid and from about 1 to about 15 percent by weight (based on the solution total weight) of ethanol, water in the amount of from about 0.4 to about 3.5 percent by weight of the total solution and optionally a pharmaceutically acceptable surfactant. | 20000525 | CZ(捷克共和国) | 20100106 | CZ294246B6;CZ298188B6;WO9525504A1;WO9822106A1;WO9509614A1;WO9701349A1;WO9607696A1 | A61K31/425 | CZ20010004293 | ALANI LAMAN A;GHOSH SOUMOJEET | CZ301308B6 | ABBOTT LAB | ||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | C07D277/28;A61K9/48;A61K31/00;A61K31/425;A61K31/426;A61K31/427;A61K31/47;A61K31/472;A61K31/4725;A61K31/496;A61K31/551;A61K31/635;A61P31/12;A61P37/04;A61P43/00 | A pharmaceutical composition is disclosed which comprises a solution of an HIV protease inhibiting compound in a pharmaceutically acceptable organic solvent comprising a pharmaceutically acceptable alcohol. The composition can optionally comprise a pharmaceutically acceptable acid or a combination of pharmaceutically acceptable acids. The solution can optionally be encapsulated in hard gelatin capsules or soft elastic gelatin capsules. The solution can optionally be granulated with a pharmaceutically acceptable granulating agent. | 19940830 | EP(欧洲专利局) | 19960703 | C07D277/28 | EP19940927973 | AL-RAZZAK LAMAN A;MARSH KENNAN C;MANNING LOURDES P;KAUL DILIP | EP0719142A1 | ABBOTT LAB | |||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | A61K31/425;A61K9/48;A61K31/17;A61K31/426;A61K31/427;A61K31/4433;A61K31/4709;A61K31/472;A61K31/4725;A61K31/496;A61K31/513;A61K31/5375;A61K31/551;A61K31/63;A61K45/00;A61K47/10;A61K47/12;A61K47/30;A61K47/42;A61P31/18;A61P43/00 | Improved pharmaceutical compositions are provided comprising one or more HIV protease inhibiting compounds having improved dissolution properties in a mixture of a fatty acid, ethanol, and water. | 20000525 | EP(欧洲专利局) | 20090422 | A61K31/425 | EP20060114684 | ALANI LAMAN A;GHOSH SOUMOJEET | EP1733725B1 | ABBOTT LAB | |||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | A61K31/513;A61K9/16;A61K9/20;A61K9/28;A61K31/426;A61K31/427 | The present invention provides a pharmaceutical dosage formulation, and more particularly, to a pharmaceutical dosage formulation comprising an HIV protease inhibitor. | 20060221 | EP(欧洲专利局) | 20100714 | WO2005039551A2;WO2004032903A2;WO0134119A2;US2001051721A1 | A61K31/513 | EP20100159672 | ROSENBERG J?RG;REINHOLD ULRICH;LIEPOLD BERND;BERNDL GUNTHER;BREITENBACH J?RG;ALANI LAMAN;GHOSH SOUMOJEET | EP2206500A1 | ABBOTT LAB | ||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | A61K31/675 | The present invention relates to an oral unit dosage form comprising Emtricitabine, Tenofovir, Darunavir and Ritonavir and a monolithic tablet comprising Darunavir and Ritonavir and their use to treat HIV infection. | 20140828 | WO(世界知识产权局) | 20150305 | US5922695A;US5935946A;US5977089A;US6043230A;US8592397B2;US8716264B2;US2014037732A1;US5210085A;US5814639A;US5914331A;US6642245B1;US7402588B2;US6335460B1;US6248775B1;US5843946A;USRE43596E;WO2013004816A1;US5541206A;US5648497A;US6037157A;US7364752B1;US8268349B2;WO2011061302A1;WO2011061303A1;WO9630025A1;WO2006135933A2;WO2009081174A2;WO2013057469A1;EP1097148A2 | A61K31/675 | WO2014IB01637 | SHAHAR NITZAN;HARONSKY ELINA;HRAKOVSKY JULIA | WO2015028875A2 | TEVA PHARMA | ||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | A61K47/22;A61K9/20;A61K31/427;A61K31/4418;A61K31/5377;A61K47/12 | Disclosed are compressed tablets containing atazanavir sulfate and an acidifying agent, optionally with another active agent, e.g., anti-HIV agents, and optionally with precipitation retardant agents. Also disclosed are processes for making the tablets, and methods of treating HIV. | 20141125 | US(美国) | 20150319 | WO2009084036A2 | A61K47/22 | US201414552772 | NIKFAR FARANAK;HUSSAIN MUNIR ALWAN;QIAN FENG | US2015080399A1 | SQUIBB BRISTOL MYERS CO | ||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | A61K47/22;A61K9/20;A61K31/427;A61K31/4402;A61K31/4418;A61K31/5377;A61K45/06;A61K47/12;B29B9/12 | Disclosed are compressed tablets containing atazanavir sulfate and an acidifying agent, optionally with another active agent, e.g., anti-HIV agents, and optionally with precipitation retardant agents. Also disclosed are processes for making the tablets, and methods of treating HIV. | 20171002 | US(美国) | 20180125 | A61K47/22 | US201715722068 | NIKFAR FARANAK;HUSSAIN MUNIR ALWAN;QIAN FENG | US2018021436A1 | BRISTOL-MYERS SQUIBB COMPANY | |||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | A61K47/22;A61K9/20;A61K31/427;A61K31/4402;A61K31/4418;A61K31/5377;A61K45/06;A61K47/12;B29B9/12 | Disclosed are compressed tablets containing atazanavir sulfate and an acidifying agent, optionally with another active agent, e.g., anti-HIV agents, and optionally with precipitation retardant agents. Also disclosed are processes for making the tablets, and methods of treating HIV. | 20181219 | US(美国) | 20190502 | A61K47/22 | US201816225493 | NIKFAR FARANAK;HUSSAIN MUNIR ALWAN;QIAN FENG | US2019125875A1 | SQUIBB BRISTOL MYERS CO | |||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | A61K47/48;A61P31/18 | Provided herein (among other things) are protease inhibitor compounds having enhanced features, along with methods for administering such compounds. For example, the subject compounds can be administered without concomitant administration of a CYP3A4 inhibitor, have increased therapeutic index and/or increased potency, and are low-resistance inducing in nature. Exemplary potent HIV protease inhibitors are mono-m-PEG3-atazanavir, mPEGn-N-darunavir (wherein n is 3 or 5), mPEGn-NHCO-saquinavir (wherein n is 5 or 7), and di-mPEG3-atazanavir. | 20090917 | WO(世界知识产权局) | 20100603 | FR2773994A1;WO2008112289A2 | A61K47/48 | WO2009US05208 | JUDE-FISHBURN C SIMONE;VANDERVEEN LAURIE ANNE;RILEY TIMOTHY A | WO2010033219A3 | NEKTAR THERAPEUTICS;JUDE-FISHBURN C SIMONE;VANDERVEEN LAURIE ANNE;RILEY TIMOTHY A | ||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | A61K9/00;A61K9/20;A61K9/28;A61K31/551 | Provided is a solid unit oral pharmaceutical dosage form of saquinavir mesylate comprising from about 60% to about 80% micronized saquinavir mesylate based on the mesylate salt, from about 4% to about 8% of a pharmaceutically acceptable water soluble binder, a pharmaceutically acceptable disintegrant, and a pharmaceutically acceptable carrier, wherein each percentage is of the kernel weight of the pharmaceutical dosage form. Also provided is a similar dosage form, wherein the saquinavir mesylate is in an amount of frorn about 200 mg to about 700 mg calculated as saquinavir free base. Further provided is the process of making the dosage form and use of the dosage form for the treatment of HIV mediated disease. | 20040705 | NZ(新西兰) | 20080430 | A61K9/00 | NZ20040544585 | ALBANO ANTONIO A;INFELD MARTIN HOWARD;PHUAPRADIT WANTANEE;SHAH NAVNIT HARGOVINDAS;ZHANG LIN | NZ544585A | HOFFMANN LA ROCHE | |||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | A61K31/675;A61K9/20;A61K9/28;A61K31/427;A61K31/513;A61K31/635 | The present invention relates to an oral unit dosage form comprising Emtricitabine, Tenofovir, Darunavir and Ritonavir and a monolithic tablet comprising Darunavir and Ritonavir and their use to treat HIV infection. | 20160223 | US(美国) | 20160714 | A61K31/675 | US201615051381 | SHAHAR NITZAN;HARONSKY ELINA;HRAKOVSKY JULIA | US2016199396A1 | TEVA PHARMA | |||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | A61K31/4418;A61K9/20;A61K9/28;A61K31/427;A61K31/551;A61K38/05;C07D213/42 | Disclosed are compressed tablets containing atazanavir sulfate, optionally with another active agents, e.g., anti-HIV agents, granules that contain atazanavir sulfate and an intragranular lubricant that can be used to make the tablets, compositions comprising a plurality of the granules, processes for making the granules and tablets, and methods of treating HIV. | 20171121 | US(美国) | 20180315 | A61K31/4418 | US201715819070 | KOO OTILIA MAY YUE;NIKFAR FARANAK;DIAZ STEVEN | US2018071270A1 | SQUIBB BRISTOL MYERS CO | |||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | A61K31/4418;A61K9/20;A61K9/24;A61K31/427 | Disclosed are compressed tablets containing atazanavir sulfate, optionally with another active agents, e.g., anti-HIV agents, granules that contain atazanavir sulfate and an intragranular lubricant that can be used to make the tablets, compositions comprising a plurality of the granules, processes for making the granules and tablets, and methods of treating HIV. | 20140702 | US(美国) | 20151112 | A61K31/4418 | US201414322478 | KOO OTILIA MAY;NIKFAR FARANAK;DIAZ STEVEN | US2015320731A1 | SQUIBB BRISTOL MYERS CO | |||
| 治疗用药 -> 化学药 -> 抑制HIV蛋白酶 | A61K31/4418;A61K9/20;A61K9/28 | Disclosed are compressed tablets containing atazanavir sulfate, optionally with another active agents, e.g., anti-HIV agents, granules that contain atazanavir sulfate and an intragranular lubricant that can be used to make the tablets, compositions comprising a plurality of the granules, processes for making the granules and tablets, and methods of treating HIV. | 20150330 | US(美国) | 20150723 | US2005256202A1;US5681583A;US2005026910A1;US2007059360A1;US2857313A | A61K31/4418 | US201514673171 | KOO OTILIA MAY YUE;NIKFAR FARANAK;DIAZ STEVEN | US2015202191A1 | SQUIBB BRISTOL MYERS CO |
Data update frequency
Annual Update